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Abstract
Ku is a key component of the Non-Homologous End Joining DNA repair pathway. Re-
cently, a function for Ku in DNA damage response (DDR) signalling was identified through
studies exploring a Ku70 S155D phosphomimetic mutant. We hypothesize that Ku70 S155D
mimics phosphorylation of Ku70 in response to DNA damage, and that Ku S155 phosphory-
lation inhibits Aurora B leading to sustained DDR activation. In this study we show that the
S155D mutant is competent for heterodimerization, and its expression does not induce DNA
damage. Phosphorylated Ku70 associates with Aurora B by co-immunoprecipitation and this
association was demonstrated in situ with Ku70 S155D. Additionally, we demonstrate that the
Ku70 S155D vWA domain is sufficient to inhibit Aurora B in an in vitro kinase assay. Finally,
Aurora B inhibitor treatment of Ku70 S155D cells does not increase the prevalence of a DDR
marker γH2AX. This work suggests that Ku70 S155 phosphorylation inhibits Aurora B which
in turn leads to DDR activation.
Keywords: DNA double strand breaks, Non-homologous end joining, DNA damage re-
sponse, Cell cycle arrest, Ku, Aurora B
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Chapter 1
Introduction
This section summarizes the prevalence of, and previous research on DNA breaks, with a
specific focus on double stranded DNA breaks, their repair, and the DNA damage response. In
addition, it introduces previous work in the field which, in turn, forms the background for the
hypothesis and objectives.
1.1 Cancer
When it comes to research regarding human disease, understanding cancer is critically impor-
tant. While all cancers are labelled under one broad umbrella, the different tissues of origin
and mutations leading to tumourogenesis and metastasis make this group of diseases extremely
complex, with each case arising in a slightly different manner. The Canadian Cancer Society
(CCS) projected that in 2016, over 200 000 people would be diagnosed with cancer, an average
of approximately 555 people per day [1]. The CCS also states that 2 in 5 Canadians are ex-
pected to develop cancer over the course of their lives, and 1 in 4 are expected to die from the
disease [1]. While these statistics are concerning, the body of research investigating cancer is
considerable and there have been immense advancements in survival rates over recent decades
[1].
While cancer is a set of over 200 distinct diseases there are commonalities between them.
Hanahan and Weinberg, coined six hallmarks of cancer which have been generally accepted
by the field: evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth
1
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signals, sustained angiogenesis, limitless replicative potential, and tissue invasion and metasti-
sis [2]. A subsequent revision of these hallmarks identified genomic instability as the most
prominent tumorogenesis enabling characteristic [3]. Genome instability is a characteristic of
cancer cells but also represents a therapeutic target. Ionizing radiation and chemotherapeutic
drugs are commonly used to kill cancer cells. These treatments induce DNA breaks which are
repaired by healthy cells while being toxic to the rapidly dividing tumour cells. Overall, the
study of deregulated proliferation, genome instability, and the associated exploitation of this
genome instability are major fields within cancer research.
1.2 Double stranded DNA breaks
DNA carries the genetic information for a cell and is therefore vital to each cell’s survival and
proper function. There are many types of DNA damage, but DNA double strand breaks (DSBs)
are one of the most disruptive and dangerous. DNA DSBs are a threat to the continuity and
integrity of DNA [4]. They are a physical break in both strands of the DNA, which means that
if left unrepaired, genetic infomation could be lost following cell division [4]. Additionally,
the incorrect repair of DNA lesions has the potential to be dangerous through recombination
and the associated generation of novel sequences [4]. These disruptions to the genome can
lead to the development of oncogenic properties [4]. Given how dangerous these DNA breaks
can be to a cell they are surprisingly common and can be created by either endogenous or
exogenous sources including: ionizing radiation, chemotheraputic agents, free radicals, and
reactive oxygen species [5]. Additonally, there are cell specific processes that create DSBs
to induce diversity in the immune system such as Variable, Diversity and Joining (V(D)J)
recombination and immunoglobulin class switch recombination [6]. Interestingly, Ciccia and
Elledge estimated the number of DSBs created per cell by some common activities including:
a body CT scan at 0.28 DSBs/cell, a 5 hour flight at 0.001 DSBs/cell, a 60 day space mission
at 2 DSBs/cell, and external beam therapy (1,800 to 2,000 mSv dose) at 80 DSBs/cell [7].
A separate group estimated that 50 DSBs may arise per cell cycle, primarily created due to
reactive oxygen species [8]. Based on these estimates and taking into consideration the huge
number of cells in the human body it is clear that efficient DNA double strand break repair
pathways are required for survival.
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1.3 Double stranded DNA break repair
The repair of damaged DNA is necessary to prevent loss of genetic information, misrepair
causing sequence alterations, or possible neoplastic transformations [9]. The importance of
DNA DSB repair is underlined by the fact that eukaryotic cells have developed three different
pathways to repair DNA DSBs [4]. These pathways are: Homologous Recombination, classical
Non-Homologous End Joining, and alternate Non-Homologous End Joining. Each of these
have a specific role in the cell and while these pathways are mechanistically different, they
converge to ensure the repair of DNA double strand breaks [4]. The decision of which pathway
acts to repair a DSB is dependent on both the cell cycle stage of the cell and the type of
ends produced in the DSB [10]. These repair pathways are frequently deregulated in cancer
[11, 12, 13].
1.3.1 Homologous recombination
Homologous recombination requires a homologous sequence in order to repair the DNA break
[4, 14]. Therefore, this repair pathway is most efficient when the cell is in either the S or G2
phase of the cell cycle, as following DNA synthesis there are two copies of each chromosome
[4, 14, 15]. The template-dependent repair by homologous recombination means that it has
high fidelity and a much lower error rate than other repair pathways [14].
There are two models for this pathway: double strand break repair (DSBR) and the second
is synthesis-dependent strand annealing (SDSA). Both models begin with the generation of
3’ single strand overhangs through strand resection by nucleases such as Mre11 and CtBP-
interacting protein (CtIP) [14, 16]. The subsequent binding of RAD51 to the ssDNA end
creates a nucleoprotein filament capable of invading into the double stranded chromosome
that is the complementary to the damaged DNA [14]. The homologous DNA is then used as
a template to repair the damaged strand [10]. Here the two models diverge. In DSBR, the
second end of the DSB is captured by the D-loop created during synthesis and two Holliday
junctions (cross shaped structures of 4 DNA strands) are produced [17]. The resolution of
these junctions can result in crossover or non-crossover products, and is therefore associated
with meiotic recombination [17]. In SDSA, the D loop does not capture the second end of the
break. Instead the newly formed DNA dissociates from the template and is able to bind to the
non invading broken DNA end [17]. In both cases the repaired strand is identical in sequence
to the template sister chromatid, making this repair less error prone than other repair pathways.
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1.3.2 Classical Non-Homologous End Joining
In the G0/G1 stage of the cell cycle the DNA has not been replicated, therefore template-
independent repair pathways have also evolved in eukaryotes [4, 14, 15]. One fast, but slightly
error prone pathway, is the classical Non-Homologous End Joining (cNHEJ) pathway which
can function throughout the cell cycle but is primarily restricted to the G0/G1 and early S
stages [10, 18]. As mammalian cells spend most of their time in the G0/G1 stage of the cell
cycle this is the primary DNA DSB repair pathway of mammalian cells, and is therefore vital
in maintaining regulation of genomic stability [6]. The cNHEJ pathway is central in this work
specifically.
The cNHEJ acts by ligating the two ends created in an DSB back together, and this process
is oulined in Figure 1.1. The repair of DSBs by cNHEJ is initiated when the Ku heterodimer
(Ku70 and Ku80), the primary DNA binding component of this pathway, encircles the ends of
the DNA break [19]. Following this initial recognition of the break, the Ku heterodimer re-
cruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and translocates along
the DNA by 1 helical turn [4, 10]. This creates the fully functional DNA-dependent protein
kinase (DNA-PK) complex, composed of Ku and DNA-PKcs. This complex then phosphory-
lates a number of targets including Ku, Artemis, X-ray Repair Cross-Complementing protein
4 (XRCC4), ligase IV, XRCC4-like factor (XLF), and other molecules of DNA-PK [4, 6]. The
phosphorylation and recruitment of these proteins, as well as the recruitment of DNA poly-
merases, creates a DNA-protein complex with the two ends stabilized and tethered together
using filaments made of XLF-XRCC4 [20].
Ligation can only occur between blunt DNA ends with 5’phosphates and 3’hydroxyl groups.
In order to process more complex ends, Artemis exhibits endonuclease activity to open hairpin
structures as well as processing of complex DNA ends [4, 21, 22]. Additionally Ku and an
XRCC4-polynucleotide kinase/phosphatase (PNKP) complex have each been demonstrated to
have end processing activity [23, 24]. At this point, the two blunt ends of the DNA are held
in proximity to each other for ligation by the XRCC4-Ligase IV-XLF complex. This complex
ligates across the break restoring the single continuous strand of double stranded DNA [4].
Finally, following repair, the stable Ku heterodimer must be removed from the DNA. Since the
two subunits of Ku are intertwined, they cannot be removed by conformational change alone.
It is therefore proposed that the removal occurs through the polyubiquitylation of Ku80 and a
ubiquitin-dependent protein degradation [25, 26].
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Classical Non-Homologous End Joining is not only responsible for the repair of DNA dou-
ble strand breaks that occur accidentally but also for those generated by cell-specific recom-
bination activating gene (RAG) proteins in the immune system [27]. This cleavage by RAG
proteins, which occurs during lymphocyte differentiation, creates fragments containing vari-
able (V), joining (J), and diversity (D) gene segments which can then be rearranged and ligated
together through the cNHEJ pathway [27]. The cNHEJ pathway is essential in V(D)J recom-
bination in the creation of antigen receptor genes [4]. This process is required for creating a
diverse set of antigen binding sites for the receptors [4]. In addition, the repair of DSBs in im-
munoglobulin class switch recombination allows for the production of distinct antibodies [4].
The deletions and insertion errors associated with cNHEJ are an advantage in these processes,
as they create diversity in sequences [4]. This role of the cNHEJ in the production of T-cell
receptors and immunoglobulins underlies the immunodeficiency seen in patients deficient for
members of the cNHEJ pathway [28, 29, 30].
1.3.3 Alternate Non-Homologous End Joining
Accompanying the two well-characterized pathway previously discussed, there exists a col-
lection of pathways that act as backup systems of DSB repair which are independent of key
proteins involved in cNHEJ and HR repair [32]. These alternate pathways have been termed
alternative Non-Homologous End Joining (aNHEJ), B (backup)-NHEJ, or microhomology-
mediated end joining (MMEJ) [32, 33]. As these names imply, this repair mechanism does not
rely on a template for the repair process but works through the alignment of microhomolgies,
short regions of DNA complementarity, on opposite ends allowing for ligation of the broken
ends [32]. Relatively little is known about this collection of pathways but they appear to be
backup repair pathways that can initiate DSB repair in cells deficient in cNHEJ capabilities
[4]. However, this set of pathways is also functional in cells that are proficient for cNHEJ
[4]. Although much remains to be characterized about this set of repair pathways, several key
factors including Poly [ADP-ribose] polymerase 1 (PARP1), CtIP, ataxia telangiectasia mu-
tated (ATM), and the Mre11, Rad50, and Nbs1 (MRN) complex are thought to facilitate the
repair [34]. There is evidence that PARP1 acts as the initial DNA break sensing factor, as well
as tethering the ends and recruiting factors for repair [32]. The recruitment of these factors
likely leads to end resection and the exposure of microhomologies at DNA ends which can
subsequently be used to ligate and repair the DNA [32]. Ligase 3 in mammalian cells has been
suggested to play a role in aNHEJ [32]. aNHEJ repair of DNA DSBs is effective but highly
error prone, commonly leading to chromosome translocations [4, 35].
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DSB recogni�on
DNA-PKcs recruitment
NHEJ factor recruitment
End processing
Liga�on
Ku70
Ku80
DNA-PKcs
Ligase IV-XRCC4
Figure 1.1: Overview of the classical Non-Homologous End Joining pathway. Upon induc-
tion of a DNA DSB, the break is recognized by the Ku70/Ku80 heterodimer. The subsequent
recruitment of DNA-PKcs completes DNA-PK at the break and leads to the recuitment of
other cNHEJ factors including Ligase IV and XRCC4. Additonally, in order to process ends:
Artemis, PNKP, and DNA polymerases are recruited. This leads to end joining and the dissoci-
ation and removal of the cNHEJ factors. The result is one continuous length of double stranded
DNA. This schematic is derived from Dueva and Iliakis, 2013 [31].
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1.3.4 DNA DSB repair pathway choice
These three classes of DNA DSB repair co-exist in each cell, therefore upon induction of a DSB
a cell must “choose” which mechanism will repair the break [4, 36, 37]. This pathway choice is
regulated and there exists competition between pathways [4]. There are a number of factors that
influence this pathway repair. The binding of Ku is a key modulator of choice which favours
cNHEJ by suppressing aNHEJ and preventing end resection which would initiate HR [38].
Additionally, p53 binding protein 1 (53BP1) and associated effector genes promote cNHEJ by
restricting end resection [36, 37]. Conversely, proteins including CtIP and Mre11 promote end
resection and therefore HR repair [36]. It has also been demonstrated that the histone code,
specifically pre-existing chromatin structures at the break, may influence pathway choice at that
location [36]. Much of this pathway competition is decided by which proteins bind first and are
therefore able to out compete and repress the other pathways. Additionally, the antagonization
of Ku70 binding by end resection is also a key step in pathway choice [39]. However, it has
also been demonstrated that in some cases bound Ku and MRN are removed from complex
DSBs in a CtIP and Mre11 dependent manner allowing for repair by HR [40]. The complex
interplay of proteins in pathway choice is also dependent on the presence of a sister chromatid
to the broken DNA, and is therefore cell cycle stage dependent [4]. Overall, the regulation of
pathway choice is vital in fast and efficient repair of DSBs.
1.4 DNA damage response
In addition to initiating the repair of a double stranded DNA break following DNA damage,
the cell mounts a DNA Damage Response (DDR) [41]. This DDR occurs in parallel with,
and in some cases is required for, DNA repair and signals to inhibit cyclin-cyclin dependent
kinase (CDK) complexes from promoting cell cycle progression, thereby arresting the cells at
the G1/S, S, and G2/M cell cycle checkpoints [42, 43]. This cell cycle arrest prevents DNA
replication and mitosis from occurring in the presence of DNA breaks [41]. This process acts
as a safeguard to preserve genetic integrity and in this role also acts to prevent neoplastic
transformation of cells [10]. Additionally, in the case of overwhelming damage, this pathway
will also stimulate senescence or apoptosis in the damaged cell [44, 45]. The overarching goal
of the DDR is to protect the cell and in the case that DNA cannot be repaired prevent the threat
of cellular deregulation to the organism [7]. This pathway is outlined below and in Figure 1.2.
Chapter 1. Introduction 8
The DDR is a highly controlled signalling network which has evolved to function primar-
ily through quick changes in post-translational modifications and transcriptional changes [46].
The initial post-translational modifications in the DDR are primarily phosphorylation and de-
phosphorylation events which allow for specific activation and inactivation of members of the
network [7, 46]. The master kinases responsible for initiation of the DDR are members of
the phosphoinositide three-kinase-related kinase (PIKK) family [10]. Specifically, ATM and
ataxia telangiectasia and Rad3 related (ATR) kinases are the master controllers of the DDR,
with much of the signalling cascade being regulated by phosphorylation states of the pathway
members [10]. A proteomic study by Matsuoka and colleagues assessed proteins phosphory-
lated at ATM and ATR consensus sequences (SQ/TQ) following induction of DNA damage
and identified over 900 phosphorylation sites on over 700 proteins [47]. This demonstrates the
vast network of proteins and phosphorylation events involved in this pathway [47]. The ATR-
dependent signalling pathway is stimulated in response to the recruitment of replication protein
A (RPA) to a single strand in end resection or at stalled replication forks, while the ATM-
dependent pathway is initiated by the inital MRN recruitment to DNA double strand breaks
following a DNA-damaging agent induction of a DNA break [7, 10, 46]. However, these path-
ways are heavily intertwined as they involve many of the same transducers and downstream
targets [46].
The ATM-dependent pathway will be of focus in this work as it is the pathway that func-
tions primarily in the repair of DSBs, however it is interesting to note that ATM-dependent
activation of ATR signalling has also been documented [46, 48]. The ATM-dependent DDR
signalling cascade begins with the recruitment of the MRN complex to a DSB [44]. This com-
plex is necessary for the recruitment, autophosphorylation, and subsequent activation of ATM
[42]. The autophosphorylation of ATM at serine 1981 is associated with it dissociating from an
inactive dimer into two active monomer particles [10]. This in turn leads to ATM phosphory-
lating a number of mediators and downstream kinases including 53BP1, histone H2AX, Nibrin
(Nbs1), checkpoint kinase 1 (CHK1), and checkpoint kinase 2 (CHK2) [10, 49]. The MRN
complex is both a sensor for DNA damage and tethers DNA ends together [10]. Specifically,
the C-terminus of Nbs1 within the MRN complex is responsible for the recruitment of ATM to
DNA DSBs leading to ATM activation [50]. The recruitment of ATM to DNA is necessary for
its activation and function in phosphorylating CHK2 and other factors which are localized to
sites of DNA damage [50].
Phosphorylated ATM and CHK2 lead to phosphorylation, stabilization, and upregulation
of p53 [42]. p53 is a key transducer within this pathway and regulates the levels of many other
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proteins through transcriptional activation. This includes p21, a cyclin-CDK inhibitor, as well
as pro-apoptotic factors Bcl-2 associated X (Bax) and p53 upregulated modulator of apopto-
sis (PUMA) [7, 51]. p21 inhibits CyclinD/CDK4/6 and CyclinE/CDK2 complexes therefore
blocking the cell cycle from progressing. Additionally, the upregulation of p53 leads to the
upregulation of wild-type p53-induced phosphatase 1 (WIP1) and mouse double minute 2 ho-
molog (MDM2) protein phosphatases which perform a negative feedback function through
inhibiting ATM and p53 [52]. This creates a cyclical oscillation in p53 which maintains the
cell cycle arrest, but likely also acts as a measurement of persistent DNA damage and signalling
for apoptosis [52]. Therefore, this pathway initially gives the cell time to repair damage before
mitosis through p21 dependent cell cycle arrest but in the event that the DNA is not repaired,
p53 persistent oscillation may lead to activation of apoptosis. The activation of caspases and
apoptosis occurs through p53-dependent activation of apoptotic factors Bax and PUMA and is
necessary to kill off cells that are unable to repair their DNA and return to a normal state [52].
Other factors, such as H2AX, that are phosphorylated by ATM are important for the re-
cruitment of DDR proteins to the break site and the associated cascade of protein modifications
[7]. H2AX is a histone variant which is incorporated into histone octamers [44]. Phosphory-
lated H2AX (γH2AX) is the most prominent modification in DDR and occurs over several
megabases around DSBs which in turn serves as a docking site for other members of the DDR
pathway [44]. Additionally, downstream targets, specifically γH2AX and 53BP1, form foci at
breaks and therefore are markers for DNA damage that can be identified using immunofluores-
cence assay [19, 44].
While the role of kinases in the DDR is well characterized, the dephosphorylation of pro-
teins by phosphatases in the DDR pathway is additonally of interest [46, 53]. Protein phos-
phatase 1 (PP1) is one of the most studied phosphatases in the DDR, as well as being one of
the most abundant [53]. PP1 has been demonstrated to regulate the DDR, specifically by su-
pressing its activation and creating a threshold for DNA damage necessary to induce a DDR
[54]. The protein Repo-Man (recruits PP1 onto mitotic chromatin at anaphase) is a target of
CDK1 phosphorylation downstream of ATM and as its name mentions, is responsible for re-
cruiting PP1 to DNA [54]. The recruitment of PP1 to DNA prevents activation of the DDR
through the modulation of ATM activity by dephosphorylating the Ser 1981 site [54]. ATM
and PP1 bind to different areas on the Repo-Man molecule. Therefore, it is speculated that
Repo-Man-dependent proximity of PP1 and ATM allows for the dephosphorylation of ATM
and the suppression of the DDR [54]. Based on this work, dephosphorylation, in opposition to
phosphorylation, aids in the regulation and threshold determination of the DDR. However, the
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phosphorylation of I-2 (an inhibitor of PP1) by ATM leads to its dissociation from PP1, acti-
vating PP1. This in turn inhibits another kinase, Aurora B, which will be described later [55].
In this example, PP1 is activated in response to DDR, supporting that the role of phosphatases
in the DDR is more complex than a simple role in maintaining a threshold for activation.
In addition to phosphorylation and dephosphorylation, many other post translational modi-
fication have been identified to occur at sites of DNA damage and in the DDR. Briefly, ubiqui-
tination, methylation and acetylation of histones, and sumoylation of proteins such as XRCC4
and Ku at the break have been identified as a few of the likely many other types of post trans-
lational modifications that also play a role in modulation of the DDR [43].
The complex network of interactions in the DDR lead overall to 2 outcomes: If the DNA
is repaired the cell can resume normal cell cycling. Otherwise, the cell activates apoptosis to
destroy the cell and protect the organism as a whole [41, 46]. As an alternative to apoptosis, the
cell can enter senescence, which functionally also removes the threat of the unrepaired break
by preventing the cell from replicating [45].
1.5 Ku
Ku acts as the initial binding component of the cNHEJ DNA repair pathway and leads to the
recruitment of factors required to repair the DSB [4]. Ku is a heterodimer that consists of a
Ku70 and a Ku80 subunit. The Ku proteins are conserved throughout eukaryotes and more
recently homologues have been identified in Archaea and Bacteria [56]. Ku is extremely abun-
dant in human cells with estimates at 400 000 molecules per cell and it binds strongly to DNA
DSBs [27]. Ku70 and Ku80 exist in cells as a heterodimer and heterodimerization appears
to be required for the stability of each individual monomer [56]. This is demonstrated by the
severely reduced levels of Ku70 in Ku80 knockout cells and visa versa [56]. The importance
of Ku70 and the cNHEJ is demonstrated in Ku70 knockout mice. These mice are viable and
fertile but are immunodeficient, exhibit premature aging, and are approximately 50% of the
size of control mice [57, 58]. In addition, Ku70-deficient mice have an increased prevalence of
thymic tumour formation [57]. Finally, cells that are deficient in Ku70 or Ku80 are extremely
radiation sensitive [15].
Ku70 (XRCC6) and Ku80 (XRCC5) were initially identified as targets of autoantibodies
in a patient diagnosed with scleroderma polymitosis overlap syndrome [33]. This pair of pro-
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Figure 1.2: Overview of the DNA damage response pathway. Upon induction of a DSB by
endogenous or exogenous factors the MRN complex acts as a DNA damage sensor. The re-
cuitment of the MRN complex leads to the autophosphorylation and activation of ATM, the
apex kinase in this pathway. ATM then phosphorylates mediators of the DDR including CHK2.
CHK2 then leads to p53 phosphorylation and activation which in turn induces p21. p21 causes
cell cycle checkpoint arrest or in states of overwhelming or unrepaired damage, apoptosis
activation. Additionally this schematic includes number of downstream markers for DDR acti-
vation such as 53BP1, γH2AX, and p21. Only some of the major components of this pathway
are shown. This schematic was derived from Sulli et. al., 2012 [49].
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teins were named based on the patient’s initials (K.U.) and their SDS-PAGE mobilities [27].
The proteins were subsequently identified as nuclear proteins with DNA binding capabilities,
specifically in a sequence independent manner for DNA discontinuities [33, 59, 60]. Subse-
quently, the Ku subunits were identified as acting in DNA repair, specifically playing a role in
the cNHEJ [4, 10, 33]. While Ku70 and Ku80 are divergent in sequence they are quite similar
in structure and they function as a heterodimer [33].
1.5.1 Ku70 structure
Ku70 is a 70 kDa protein that is composed of 3 major domains: a core DNA binding domain, a
helical C-terminal domain, and a N-terminal von Willebrand A (vWA) like α-β domain (Figure
1.3) [61, 62]. The core domain is responsible for the heterodimerization of Ku70 with Ku80
[33]. Additionally, the formation of the heterodimer, through the core domains, creates a ring
structure lined with positive charges which bind DNA breaks in a sequence independent man-
ner [33]. The C-terminal domain of Ku70 is the most divergent region from Ku80 in structure
[33]. The C-terminal of Ku70 is much smaller than that of Ku80 and consists of a SAP do-
main (SAF-A/B, Acinus, and PIAS motifs) which is linked to the rest of the protein through
a linker region [63]. The deletion of C-terminal domain decreases DNA DSB binding of Ku
suggesting that it is involved in DNA interaction [63]. The N-terminal vWA like domain is
composed of a Rossmann fold type six-stranded β-sheet with one antiparallel strand [61]. The
amino end of the vWA domain is in contact with the bound DNA while the carboxyl end faces
away from the DNA [61]. This means that the outer side of the vWA domain protrudes from
the complex formed at a DNA DSB where it could be involved in protein-protein interactions
[33]. Many characterized vWA domains are found within proteins of the extracellular matrix
as well as being involved in cell adhesions [64]. In these roles, the vWA is frequently involved
in protein-protein interactions [64]. However, interestingly, very few protein interactions have
been mapped to this region of Ku70 [33].
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Figure 1.3: Domains and structure of Ku70 and Ku80. A) Schematic of the domains of Ku70
and Ku80. There are three main domains in each: the N-terminal vWA domain (in Ku70 the
S155 site is highlighted in yellow), the core DNA binding domain, and the divergent C-terminal
domain. The black bar in each denotes the location of the nuclear localization signal. B) The
crystal structure of the Ku heterodimer creating an asymetric ring encircing the bound double
stranded DNA. The specific domains of Ku70 are colour coded to the schematic in A and
the S155 site is highlighted in yellow. The Ku70 and Ku80 C-terminal domains are partially
unstructured and therefore are not fully present in the diagram. Structure was obtained from
PDB:1JEY [61].
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1.5.2 Functions for Ku outside the cNHEJ
In addition to its roles in cNHEJ and the associated V(D)J pathway, Ku70 and Ku80 have been
demonstrated to play roles in other cellular processes [33, 56].
Ku proteins have been implicated in the movement of mobile genetic elements [56]. The
integration of transposons, retrotransposons, and retroviruses, or their products, into the host
genome occurs in a similar fashion to V(D)J recombination [56]. Ku has been demonstrated
to facilitate integration of the Ty1 retrotransposon in S. cerevisiae [65]. Addtitonally, Ku70
has been demonstrated to interact with the viral genome and Early 1 A (E1A) proteins in
adenovirus [66]. It is probable that mobile genetic elements have taken advantage of the role
of Ku in DNA repair.
Ku has additionally been suggested to have a cytoplasmic function in apoptosis [67, 68].
Ku70 has been demonstrated to be necessary for the deubiquitination of induced myeloid
leukemia cell differentiation protein (Mcl-1) at the K48 position [67]. This deubiquitination
stabilizes Mcl-1 and leads to the suppression of apoptosis [67]. In a similar role, Ku70 re-
presses apoptosis by sequestering Bax in the cytoplasm [68, 69]. The sequestration of Bax is
also associated with Ku70-dependent deubiquitination of Bax [69].
An important role for Ku occurs at telomeres, the DNA-protein structures at the end of
each chromosome. While Ku knockouts in mouse models are viable, several studies into the
creation of Ku knockout human cell lines have demonstrated lethality [70, 71]. This lethal-
ity through induction of apoptosis has been associated with a role for Ku at telomeres [70].
Similar to DSBs, telomeres are an end to the DNA double strand helix. Therefore it might be
expected that Ku and other members of DSB repair pathways may bind and function at telom-
eres. However, the structure of telomeres has evolved to prevent activation of DNA DSB repair
pathways, as to not erroneously join them to another chromosome or broken strand of DNA
[33]. Contrary to this theory, Ku binds at telomeres and plays an important role in stability
[72]. Ku deficient mice and human cells both show altered telomere length and stability [73].
Ku acts to prevent recombination and degradation at telomeres [72, 74]. Ku also plays a role in
telomere lengthening, as demonstrated by its involvement in the recruitment of telomerase to
telomeres [75]. Finally, a study in fungus, Ustilago maydis specifically, concluded that in this
organism Ku acts to suppress activation of the DNA damage response at telomeres [76]. In this
work, under a repressible expression system, the reduction in Ku expression was associated
with cell cycle arrest at the G2 checkpoint due to activation of the DDR in a MRN dependent
manner [76].
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1.5.3 Post-translational modifications of Ku70
Ku has been shown to be post-translationally modified in a variety of ways to modulate its
many characterized functions.
Ku70 is targeted for acetylation at multiple lysine residues [68, 77]. These acetylation
events alter the funtion of Ku70 and can dimimish its ability to repair DNA damage [78].
One example of this is the acetylation of Ku70 by the inhibitor of histone acetyltransferases
(INHAT) complex leading to Bax-mediated apoptosis, while Ku not acetylated at this position
normally sequesters Bax in the cytoplasm [68, 78, 79]. In contrast, Ku acetylation at a different
lysine residue leads to a reduction in DSB affinity [77]. Therefore the manipulation of this
acetylation site by Histone Deacetylase (HDAC) activity has been suggested to regulate the
efficacy of cNHEJ [77]. As such, treatment with an HDAC inhibitor provides a putative cancer
treatment in the sensitizing of cells to chemotherapy by reducing Ku functionality in cNHEJ
[77].
Another set of Ku70 post-translational modifications that have been identified are involved
in the removal of Ku70 from DNA. Ubiquitination of Ku80 disrupts its DNA binding and
may play a role in the removal of the heterodimer [25, 26]. Similarly, research by Brown
and colleagues has demonstrated a neddylation-dependent ubiquitination of Ku70 [80]. These
authors suggest that the result of these two types of post-translational modifications promotes
the release of Ku from repaired DSBs, a necessary function to complete cNHEJ [80].
Finally, Ku70 is phosphorylated under specific conditions [81, 82, 83]. Chan and colleagues
identified that in vitro DNA-PK phosphorylates Ku70 at the serine 6 position, a sequence which
is divergent from the SQ/TQ consensus sequence of DNA-PK phopshorylation [83]. The au-
thors demonstrated that this residue is phosphorylated at low levels in vivo [84]. However,
this serine 6 phosphorylation was not required for cNHEJ repair [83, 84]. An additional study
using bacterially expressed Ku70 identified serine 51, a SQ consensus sequence for phospho-
rylation site, as an additional DNA-PK phosphorylation site [85]. More recently it was shown
that Ku70 phosphorylation at five residues in the 305-316 amino acid area led to increased
end-resection, a characteristic of HR repair [86]. This result supports that post-translational
modification may play a role in DSB repair pathway choice [86]. A similar body of research
showed that Ku70 phosphorylation by cyclin-CDK complexes at specific times within the cell
cycle interfered with the interaction of Ku with the repair origin. The subsequent dephos-
phorylation event following mitosis, allows for Ku-DNA DSB binding in G0 and G1, also
supporting its role in repair pathway choice [81]. DNA-PK phosphorylation of Ku70 has also
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been linked to activation of Bax-mediated apoptosis through altering the interaction of Ku70
and Bax [87]. Research into the identification and characterization of phosphorylation of Ku70
at tyrosine 530 demonstrated that the phosphorylation at this site decreases acetlyation there-
fore interplaying with the previously described acetylation of Ku70 in regulation of apoptosis
[88]. Phosphorylation of Ku has also been demonstrated to be increased in cancer cells [89].
Phosphorylation of Ku70 at the serine-27 and serine-33 positions increased following irradia-
tion treatment [89]. In addition, cells expressing an alanine residue at these positions (which
block phosphorylation) showed a slower repair of DNA DSBs by comet assay as well as an
altered proliferation before and after irradiation [89]. The authors concluded that higher levels
of pKu70 in cancer cells was associated with an increase in DNA repair but with a decrease
in accuracy of repair. From this, they proposed that pKu70 may contribute to the resistance of
tumours to DNA damage inducing treatments [89].
Overall these studies demonstrated that Ku70 post-translational modifications play a variety
of roles in pathway regulation within the cell.
1.5.4 Ku70 vWA domain mutants
The vWA domain of Ku70 was of specific interest in the study from Fell and Schild-Poulter
[90], as this family of domains is classically known to be a protein-protein interaction do-
main but very few Ku70-interacting proteins had been mapped to this domain [19, 56, 68, 90].
Therefore, in an attempt to determine important structural and sequence specific functions of
this region the authors created point mutants within the Ku70 vWA domain [90]. Ku70 WT
and mutants were expressed in Ku70 knockout MEFs using a retroviral expression system
[90]. Unexpectedly, a S155A/D156A double mutant increased cell survival, relative to wild-
type (WT), following DNA damage induction by irradiation (IR) [90]. Analysis by pulse field
gel electrophoresis and an in vivo plasmid repair assay established that this mutation did not
affect DNA repair efficiency, therefore suggesting that the increased survival was not repair-
dependent. Instead, the authors identified changes in the DDR and defects in the activation of
apoptosis [90]. Specifically, differential gene expression of several apoptosis-related, activating
transcription factor 2 (ATF2)-regulated genes was identified. Futher, Ku70 was demonstrated
to repress ATF2 activation, and this repression was enhanced in Ku70 S155A/D156A express-
ing cells [90]. Finally, a S155A Ku70 mutant was sufficient for survival following IR, and a
Ku70 S155D phosphomimetic Ku70 reversed this effect. Therefore, the authors implicated the
Ku S155 site in the activation of apoptosis through its phosphorylation [90].
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1.6 Ku70 S155
This work suggested an important role for Ku70 S155 in DNA damage signalling and the
activation of apoptosis. The mutation of the serine to an alanine at the 155 site represents a loss
of the OH functional group (Figure 1.4). The OH group on serine side chains are a common site
for phosphorylation as a regulator of signalling. Upon mutation to an alanine the site can not be
phosphorylated, which Fell and Schild-Poulter proposed could explain the effects of the S155A
mutant following irradiation [91]. The authors therefore created a phosphomimetic mutation
of the serine to an aspartic acid, Ku70 S155D (Figure 1.4). The expression of the Ku70 S155D
mutant in Ku70−/− MEFs increased cell senstivity to DNA damage [90]. Specifically, these
cells were hypersensitive to IR to an even greater extent than Ku70-deficient cells. This data
is consistent with the S155 site being a site of phosphorylation in response to DNA damage
which regulates apoptotic pathways [90].
Fell and colleagues later went on to use mass spectrometry to demonstrate that Ku70 S155
position is phosphorylated in response to IR [91]. Through continued work with the S155A and
S155D Ku70 mutants, the authors discovered that the Ku70 S155A expressing MEFs have a
slight increase in proliferation relative to WT. Conversely, Ku70 S155D confers a pronounced
growth defect relative to WT and this was associated with the induction of cell cycle arrest
at the G1/S and G2/M cell cycle checkpoints (Figure 1.5) [91]. The activation of cell cycle
checkpoints was also supported by the differential gene expression stimulated by Ku70 S155D
expression. Specifically, expression of genes that promote transition through the checkpoints,
including Cyclin D, CDK 6, and Cyclin B, were downregulated. In addition, the Ku70 S155
position was demonstrated to regulate ATM activation, induction of p21, and appearance of
γH2AX and 53BP1 foci [91]. In WT cells, upon irradiation, ATM was phosphorylated and ac-
tivated, p21 was induced, and γH2AX and 53bp1 foci were present. However, in Ku70 S155A
expressing MEFs these outcomes were dampened. Conversely, Ku70 S155D MEFs showed
constitutive ATM activation, p21 expression, and the presence of DDR markers γH2AX and
53BP1 foci, under normal culturing conditions (i.e. without IR treatment or other exogenous
sources of DNA damage) [91]. The authors also demonstrated that Ku-DNA binding was not
necessary for the induction of DNA damage markers and cell cycle arrest. The Ku70 S155D
vWA domain is sufficient to induce this response, in both a Ku null and WT Ku background.
Therefore, exogenous Ku70 S155D vWA domain is dominant over endogenous Ku70 in this
pathway. Taken together, Ku70 S155D, which mimics Ku70 phosphorylation following DNA
damage, activates ATM and a DNA damage response [91].
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Figure 1.4: Structure of Alanine, Aspartic Acid, Serine, and Phospho-Serine. The side chain
of the amino acid present at the S155 position appears to be of importance in DDR signalling.
This figure compares the structure of the side chain of the studied amino acids. A) Serine is
present at the 155 site in WT Ku70. Serine has an OH functional group as its side chain. B) The
OH of a serine is a common site for phosphorylation. C) Alanine has no side chain, meaning
that when it is incorporated at a site in place of serine there is no longer the opportunity for
phosphorylation. D) Aspartic Acid has a side chain that resembles a phosphorylated serine
group in structure and size and is therefore considered a phosphomimetic.
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Figure 1.5: Ku70 mutants exhibit altered proliferation and cell cycle profiles. A) S155 mutants
display abnormal growth rates in normal culturing in absence of DNA damage. S155 mutant
expressing MEFs were plated at equal density then cells were counted on each day for 5 days,
with growth rate shown as a percentage of day 1. S155A expressing MEFs proliferate at a
significantly faster rate than WT MEFs. Ku70 S155D MEFs do not proliferate. B) Ku70
S155D expressing MEFs arrest in G1 and G2 phases. Flow cytometry analysis of Ku70 MEFs
measuring propidium iodide content and EdU incorporation in order to determine the percent
of cells in each stage of the cell cycle based on DNA content. This figure was adapted from:
Ku70 Serine 155 mediates Aurora B inhibition and activation of the DNA damage response in
Scientific Reports by Fell et. al. [91].
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1.7 Aurora B kinase
In a pull-down screen for proteins interacting with Ku70 S155D, Aurora B kinase was identified
[91]. This interaction was verified by co-immunoprecipitatation of Aurora B with a Ku70
S155D peptide but not with a corresponding WT Ku70 peptide. In addition, Aurora B from
Ku70 S155D expressing MEFs co-immunoprecipitated with Ku70, while this was not the case
in WT Ku70 expressing extracts [91].
Aurora B is a well characterized serine/threonine mitotic kinase as well as being a member
of the Aurora Kinase family [92]. This small group of kinases consists of 3 human proteins:
Aurora A, Aurora B, and Aurora C [93]. Aurora A and B are similar in structure but have dis-
tinct functions within mitosis throughout the body, while Aurora C, which is structurally even
more similar to Aurora B, is found almost expressed primarily in the testes [92]. These pro-
teins each have distinct roles. Deregulation of these kinases leads to polyploidy and has been
linked to tumour progression [93, 94]. Therefore, these Aurora kinases are putative antitumour
treatments, specifically because they regulate cell division, a key step in the development and
progression of tumours [93]. Encouraging results have been shown with the Aurora kinase
inhibitors [95, 96, 97].
Aurora B specifically, was originally identified in Drosophila where a mutated form led
to monopolar spindles which in turn led to its naming after the Aurora Borelalis [94]. Au-
rora B acts in mitosis as the catalytic subunit of the chromosomal passenger complex (CPC)
[94, 98]. In addition to Aurora B, there are 3 other core members of the CPC: INCENP which
provides a scaffold basis for the complex and aids in Aurora B activation, Survivin which aids
in targeting of the complex and has a debated role in inhibiting apoptosis, and Borealin which
aids in directing localization of the complex [92, 93, 98]. There is an additional fifth chro-
mosomal passenger, telophase disc-60 kD (TD-60), which is necessary for the full activation
of Aurora B kinase activity [99]. This complex has been demonstrated to move throughout
the nucleus playing a role in many of the crucial stages of mitosis progression. Specifically,
Aurora B, in the CPC, plays a role in: phosphorylation of Histone H3 and related chromosome
condensation, chromosome-microtubule interactions, spindle assembly, centromeric cohesion,
and cytokinesis [92, 93, 98].
Although levels of Aurora B appear to be low in G1, Aurora B has been demonstrated to
be expressed and have functions outside of mitosis [100, 101]. Aurora B has been identified as
a regulator of the G1/S cell cycle checkpoint in a mTOR signalling dependent manner [100].
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Additionally, it has been shown to regulate the postmitotic checkpoint and endoreplication
through phosphorylation of Retinoblastoma protein (Rb), which can lead to polyploidy when
cells are treated with an Aurora B inhibitor [101]. Aurora B also acts at the G2/M checkpoint
where it phosphorylates the transcription factor Yin Yang 1 (YY1) [102]. Also at the G2/M
checkpoint, Aurora B acts in the phosphorylation of Histone H3 and it appears that this activity
regulates the dissociation of Heterochromatin Protein 1 (HPA1α) from heterochromatin [103].
Interestingly, Ku70 has been demonstrated to interact with HP1α in a yeast two-hybrid screen
[104]. These functions of Aurora B suggest that it may play functions outside of mitosis and
specifically at cell cycle checkpoints.
In addition, Aurora B and the DNA damage response have been previously linked through
Aurora B phosphorylation of ATM, a key kinase of the DDR [105]. This phosphorylation
on Ser1403 of ATM, by Aurora B, leads to its activation in mitosis independent of the DNA
damage state of the cell [105]. In a thiophosphate labelling screen for targets of Aurora B,
many chromatin associated proteins were identified as expected, but in addition somewhat un-
expectedly, some DNA damage response proteins were identified [106]. Specifically Telomere-
associated protein RIF1, FACT complex subunit SPT16, and DNA-PKcs [106]. Additionally,
Aurora B has been demonstrated to play a role outside of mitosis in the phosphorylation of p53
leading to ubiquitin-dependent p53 degredation [107, 108]. This activity of Aurora B decreases
p53 transcriptional activity [107] and therefore also decreases p53-activated cell cycle arrest as
outlined in the DDR section and Figure 1.2. In summary, it appears that in addition to roles in
directing mitosis, Aurora B may also play a role in the DDR.
The identification of Aurora B as interacting with a Ku70 S155D peptide and Ku70 S155D
by co-immunoprecipitation but not with the corresponding WT Ku70 was intruiging because of
the previously stated function of Aurora B in the regulation of the cell cycle and its association
with key proteins in the DDR. In addition, further testing and literature review demonstrated
that chemical inhibition of Aurora B shows many of the same phenotypes as expression of the
Ku70 S155D mutant. For example, treatment with inhibitors of the Aurora kinases, specifi-
cally VX-680, causes endoreplication, induction of p21 expression, arrest in the G1 (or pseudo
G1) state, reduction in Histone H3 phosphorylation, and activation of DNA damage response
markers such as 53BP1 and γH2AX foci [91, 95, 109, 110]. Similarly, Aurora B knockout
cells showed a decreased entry into S phase (supporting cell cycle arrest at the G1 cell cycle
checkpoint), premature mitotic exit, induction of p21 expression, and defective Cdk1 activity
[111]. Gizatullin and colleagues additionally show that siRNA depletion of Aurora B alone
caused a small increase in the proportion of cells with G2/M DNA content. Overall, the con-
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stitutive activation of ATM, induction of p21, cell cycle arrest, and presence of DNA damage
markers seen upon expression of Ku70 S155D were also present upon inhibition of Aurora B
[91].
Additionally, micro-irradiation experiments in the work by Fell et. al. (2016) demonstrate
that Aurora B is recruited to sites of DNA damage. This change in localization supports that
Aurora B may play a role in the signalling following DNA double strand breaks, as much of
the initial signalling occurs in proximity to the break.
1.7.1 Regulation of Aurora B
The activity of Aurora B is regulated by many different proteins. From interaction with co-
factors in the CPC, such as INCEP, to phosphorylation by kinases such as CHK1, Aurora B
requires many other proteins to become fully activated [92]. As proof of this, Hengeveld and
others showed that bacterially expressed Aurora B is not sufficient to phosphorylate Histone
H3 in a in vitro kinase assay [106]. However, endogenous Aurora B immunoprecipitated from
cells does phosphorylate Histone H3 in a similar in vitro kinase assay [91, 106].
Additionally, there are a number of proteins that have been demonstrated to inhibit Aurora
B activity. Specifically, phosphatases such as protein phosphatase 1 (PP1) and protein phos-
phatase 2A (PP2A) both bind to and inhibit Aurora B kinase activity [92]. Futhermore, the
PP1 based inhibition of Aurora B, is dependent on ATM phosphorylation of I-2 (inhibitor-2)
leading to its dissociation from PP1 [55]. In an opposing pathway, PP1 and PP2A control the
threshold for DNA damage reponse activation through regulation of ATM activation [54]. Sim-
ilar work by Monaco and colleagues, showed that Aurora B is inhibited in response to DNA
damage. These authors demonstrate that this is due to DNA damage dependent activation of
poly(ADP-ribose) polymerase (PARP)1, and subsequent pol(ADP-ribosyl)ation of Aurora B
[112]. This work proposes additional links between Aurora B regulation and DNA repair and
the DNA damage response pathways.
Since Aurora B is highly regulated, had been previously associated with DNA damage
response and repair pathways, and its chemical inhibition led to similar phenotypes as the
expression of Ku70 S155D, Fell and colleagues proposed that Ku70 phosphorylation, or ex-
pression of the phosphomimetic Ku70 S155D, could lead to the inhibition of Aurora B [91].
Both in vitro and in vivo kinase assays for Aurora B activity (phosphorylation of Histone H3)
demonstrated that Aurora B in Ku70 S155D expressing cells had lower kinase activity than
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Aurora B in WT Ku70 expressing cells [91]. This supports that Ku70 S155D inhibits Aurora
B kinase activity leading to DDR activation.
1.8 Hypothesis and objectives
Based on this work, I hypothesize that Ku70 S155D mimics phosphorylation of Ku70 in re-
sponse to damage, and that Ku70 S155D and the corresponding phosphorylation of Ku70 S155
are able to inhibit Aurora B leading to a sustained activation of the DDR and cell cycle ar-
rest through activation of DDR signalling. The main goal of this work is to determine how
phosphorylated Ku70 is able to inhibit Aurora B and mediate the DDR and cell cycle arrest,
through experimentation using the phosphomimetic Ku70 S155D. A theoretical model of how
Ku70 S155D phosphorylation may act in DNA Damage response is shown in Figure 1.6.
The plan for this project involves 3 objectives: The first objective is to investigate the func-
tional properties of Ku70 S155 mutant re-expression in Ku70−/− cells. The second objective
is to characterize the role of Ku70 S155D in inhibition of Aurora B and the activation of the
DDR. The final objective is develop a Ku70-inducible expression system.
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Figure 1.6: Hypothetical model for the cells response to DNA damage through Ku70 phos-
phorylation. Following DNA damage Ku initiates repair through recruitment of the repair
complex. A) We propose that if DNA repair is completed, Ku70 S155 does not become phos-
phorylated and no Aurora B inhibition occurs. In this context we propose that some factor,
such as ATM, is not activated and leaves Aurora B fully functional. B) In the case of persistent
or overwhelming DNA damage, we propose that Ku70 is recruited to the break and becomes
phosphorylated. This phosphorylation is mimicked in our studies through expression of Ku70
S155D. In the case of Ku70 S155D expression or phosphorylation of Ku70, some factor, such
as ATM, is activated to inhibit Aurora B. This phosphorylation of Ku70 also then leads to the
DDR and cell cycle checkpoint activation phenotype.
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Methods
This chapter outlines the materials used in this work and the specifics of the procedures fol-
lowed to complete the experiments.
2.1 Plasmid constructs
Full length Ku70 WT, S155D and S155A were previously cloned into the pMSCVpuro vector
for infection into mammalian cell lines [90].
WT Ku70-HA was created using the pMSCVpuro WT Ku70 construct as a template for
polymerase chain reaction (PCR). The DNA was amplified with a forward primer at the begin-
ning of Ku70 and a reverse primer which removed the stop codon and introduced a C-terminal
HA-tag as well as an EcoRI cut site (See primer table: Table A.1 (Appendix)). Digestion of
this PCR product with EcoRI cuts after the HA-tag and within Ku. This fragment was then
used to swap out the C-term in WT Ku70 pMSCVpuro, thereby introducing the HA-tag. To
create the mutants PSI and XhoI enzymes were used to swap the middle section of Ku70 from
the previously made Ku70 pMSCVpuro mutants into the new WT Ku70-HA construct.
The Ku70 WT and S155D vWA fragment for bacterial expression was created by Dr. Vic-
toria Fell using PCR primers to produce a fragment (aa 1-252) of Ku70 from the full length
pMSCVpuro construct. This N-term fragment was subcloned into the pET-28-a (Novagen,
Millipore) expression vector.
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A tetracycline repressible system was created by cloning full length (FL) Ku70 WT and
S155D into the pBIG2r vector [113]. Ku70 was PCR amplified from the pMSCVpuro con-
structs using primers with additional restriction enzymes sites (See Table A.1 (Appendix)).
These FL Ku70 WT and S155D PCR fragments were then inserted into the multiple cloning
site of the pBIG2r vector, creating an expression vector that could be transfected into mam-
malian cell lines and would allow for tetracycline repression of Ku70 expression.
2.2 Cell culture
All cell types were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented
with 8% fetal bovine serum (FBS), 1% sodium pyruvate, and 1% glutamine (Wisent, St. Bruno,
Quebec, Canada) at 37oC and under 5% CO2. For MEFs, media was additionally supplemented
with 0.05% 2-mercaptoethanol (Sigma-Aldrich, Oakville, Ontario, Canada). HeLa cells were
cultured in DMEM.
Ku70 knockout (Ku70−/−, KO) MEFs were obtained from S. Matsuyama (Case Western,
Cleveland [114]) and were retrovirally infected with pMSCV containing WT or mutant Ku70
(S155A or S155D) or empty pMSCV vector. This was done as previously described [90] using
the primed media from Phoenix-AMPHO Human Kidney cells (ATCC CRL-3213) transfected
with the constructs to create the viral packaging for MEF infection. Once infected, MEFs were
maintained under 2.5 µg/mL puromycin.
Phoenix-AMPHO cells were also transiently transfected with Ku70-HA constructs to show
interactions with Ku80 (see Transfections).
Ku70−/− MEFs were transfected with Ku70 WT and S155D constructs in the pBIG2r ex-
pression vector (see Transfections). Stable integration was selected for by treatment with 300
µg/mL of Hygromycin-B (Wisent) at 24 h after transfection and the suppression of the expres-
sion of Ku70 was achieved by the addition of 6 µg/mL of tetracycline (Bioshop) at 4 hours
after transfection. In order to induce Ku70 expression, the media above the cells was removed,
cells were washed in phosphate buffered saline (PBS)(Wisent) and DMEM with hygromycin
but without tetracycline was added.
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2.2.1 Cell culture treatments
For all treatments, cells were seeded at least 1 day prior to treatment. Plates of cells were
treated at a confluency in the range of 70-90%.
Transfections
Transfection of Pheonix-Ampho cells was done using Calcium phosphate reagents: 0.13M
CalCl2 in HBS (25 mM Hydroxymethyl piperazineethanesulfonic acid (HEPES) pH 7.4, 140
mM NaCl, 6 mM Dextrose, 0.75 mM Na2HPO4, and 5 mM KCl)[90]. These cells were then
harvested after 24 hours or the media above the cells was used to infect MEFs (as previously
described [90]).
Transfection of MEFs with the pBIG2r Ku70 constructs was done using with JetPrime
transfection reagent and buffer (PolyPlus Transfection, Illkrich, France). 8 µg of DNA was
used to transfect a 10 cm plate of Ku70 KO MEFs. Plates were then subjected to selection
using hygromycin and Ku70 expression was suppressed with tetracycline (See tissue culture
section above).
Irradiation
DNA damage was induced by X-ray irradiation of cells using a Faxitron RX-650 X-ray cab-
inet (Faxitron X-ray LLC, Lincolnshire, IL, USA). Depending on the experiment, cells were
irradiated at 1-40 Gy using a dose rate of 1.42 or 3.75 Gy/min.
Aurora B chemical inhibition
The Aurora B specific inhibitor AZD-1152 (Sigma-Aldrich) was diluted in Dimethyl sulfoxide
(DMSO) and used at a final concentration of 20 nM in culture (20 µM stock diluted 1:1000
in media). Inhibitor or DMSO vehicle was added to Ku70 WT and S155D expressing MEFs,
which were then incubated for 24 hours before fixation for immunofluorescent assay.
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2.3 Nuclear extracts
To exclusively collect nuclear proteins, cells were washed with PBS and scraped into PBS for
collection of cell pellets by centrifugation. Cell pellets were resuspended in NE Buffer A (10
mM HEPES pH 7.9, 1.5 mM MgCl2. 10 mM KCl) supplemented with 0.5 mM DTT and 0.2
mM PMSF and incubated for 10 minutes on ice. NP-40 was added to the solution to a final con-
centration of 0.2%. The solution was then centrifuged to collect the pellet containing nuclei.
The supernatant containing the cytoplasmic fraction was removed and the pellet was resus-
pended in NE Buffer C (20 mM HEPES pH 7.9, 25% glycerol. 450 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA) supplemented with fresh inhibitors (0.2 mM phenylmethane sulfonyl fluoride
(PMSF), 1 mM Dithiothreitol (DTT), 1 g/mL leupeptin, 10 g/mL aprotinin, 1 g/mL pepstatin,
1 mM Sodium fluoride (NaF), and 1 mM Sodium orthovanadate (Na3VO4))(Obtained from
BioShop, Burlington, Ontario, Canada). Finally, nuclear extracts were collected from the su-
pernatant following a 5 minute centrifugation at 13,000 rpm at 4oC. Extracts were quantified
using Bradford assay and were stored at -80oC.
2.4 Antibodies
Antibodies were used for western blot analysis, immunofluorescence assay, and immunopre-
cipitation. A list of relevant antibodies, their dilutions for use, and where they were obtained
from is available in Table B.1 (Appendix).
2.5 Immunoprecipitation
To prepare extracts for immunoprecipitation (IP), nuclear extracts were diluted 1:3 in No Salt
Co-IP Binding Buffer (25 mM HEPES pH 7.9, 0.5 mM EDTA, and 12% glycerol) supple-
mented with inhibitors (PMSF, DTT, leupeptin, pepstatin, aprotinin, NaF, Na3VO4), at the same
concentrations as for nuclear extracts. Extracts were pre-cleared with 3 µL of pre-washed Pro-
tein G magnetic beads (EMD Millipore, Billerica, Massachusetts, USA) with agitation at 4oC
for 30 minutes. The beads were removed and the antibody for immunoprecipitation was added
to the extract (0.1 µg of antibody for every 100 µg of protein extract) and incubated for 2 hours
at 4oC with agitation. To capture the antibody and it’s bound proteins, 10 µL of pre-washed
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Protein G magnetic beads were added to the solution for a 1 h incubation. Beads were then
precipitated using a magnetic rack, and were subsequently washed using Co-IP binding buffer
(No Salt Co-IP binding buffer supplemented with 0.1% NP-40 and 60 mM KCl). Immunopre-
cipitates were then ready for use in kinase assay or to be analyzed by western blot.
2.6 Western blotting
Western blots were performed by subjecting proteins to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) on gels ranging from 8-15%. Samples were prepared by
adding 1/6 the total volume of SDS loading dye (0.35 M Tris pH 6.8, 12% SDS, 30% Glycerol,
600 mM DTT, 0.06% bromophenol blue)and boiling. Following protein separation, the gel was
equilibrated in semi-dry transfer buffer (50 mM Tris, 40 mM glycine, 20% methanol) for 10
minutes. In parallel, a polyvinylidine difluoride (PVDF) membrane was prepared by dipping
in methanol then equilibrating in semi-dry transfer buffer. Western blotting was carried out in
a Bio-Rad Trans-Blot Turbo transfer system (Bio-Rad, Mississauga, Ontario, Canada), with
three pre-soaked filter papers on each side of the gel-membrane transfer. Transfers were done
at 2.5 amperes and 25 volts for 25 minutes.
Following transfer, the membrane was blocked in 5% non-fat dry milk powder (No Name
brand) prepared in Tris Buffered Saline (50 mM Tris-Cl, pH 8; 150 mM NaCl) + 0.05%
Tween-20 (TBS-T). The membrane was subsequently incubated, for 1 h at room temperature or
overnight at 4oC, with primary antibodies diluted in 5% milk in TBS-T (See Table of antibodies
for identities and dilutions). The blot was washed three times using Tris buffered saline-Tween-
20 (TBS-T), and was incubated with species specific secondary antibodies, washed three times,
and developed using Clarity Western ECL substrate (Bio-Rad, Mississauga, Ontario, Canada).
Image exposures of western blots were collected using a Molecular Imager ChemiDoc XRS
system and the associated Image Lab Software (Bio-Rad, Mississauga, Ontario, Canada).
In addition to creating images for publication, the Image Lab software was also used for
the quantification of protein bands on western blots.
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2.7 Immunofluorescence assay
Immunofluorescence assay was performed by first seeding MEFs on coverslips. One day after
seeding, or following treatment, cells were washed three times in PBS and were fixed onto
coverslips using 3% paraformaldehyde (BioShop). The coverslips were then washed again
three times and stored a 4oC. Next, 0.5% Triton X-100 (BioShop) was used to permeabilize
the cells, and was washed off with 3 subsequent washes of PBS. Cells were then blocked in
5% FBS (Wisent) prepared in PBS. Coverslips were incubated overnight at 4oC with light ag-
itation in primary antibody prepared in 5% FBS (See Table of antibodies for identities and
dilutions). Primary antibody was washed off in PBS washes and coverslips were then incu-
bated with species-specific, AlexaFluor 488/647 secondary antibodies (Invitrogen). Secondary
antibodies were used at a 1:1000 final dilution in 5% FBS solution. Antibody was washed off
in PBS washes, and coverslips were briefly air dried before mounting on glass slides with Pro-
long Diamond Antifade Mountant with 4’,6-diamidino-2-phenylindole (DAPI) (ThermoFisher
Scientific, Rockford, Illinois USA).
Imaging for immunofluorescence assay was completed at 20 or 40x magnification with an
Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan) and with Image-Pro Plus
software (Media Cybernetics, Rockville, Maryland, USA). Images were analyzed and prepared
with ImageJ software [115].
2.8 Comet assay
Comet assays were conducted to assess DNA damage. Ku70 S155D or WT expressing MEFs
were either untreated, irradiated over a range of doses, or treated with hydrogen peroxide
(H2O2) in preparation for comet assay. They were subsequently stored on ice before harvesting
by scraping in PBS. Cells were counted using a hemocytometer and diluted in PBS to a final
concentration of 1 x 105 cells/mL. From this solution, approximately 3000 cells were diluted
1:10 in low melting point agarose and mounted on slides.
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2.8.1 Neutral comet assay
Neutral comet assay was done using the Enzo Comet SCGE assay (Cedarlane, Burlington, On-
tario, Canada). The protocol described by the manufacturer was followed. Briefly, Ku70 WT
and S155D expressing cells were compared to WT expressing cells that were treated with 100
µM of H2O2 or 40 Gy of irradiation and incubated on ice immediately to prevent DNA repair.
Cells diluted in PBS were mixed with 1% low melting point agarose which was cooled to set
on coated coverslips, creating a gel matrix with cells embedded in it. These cells were then
subjected to lysis buffer and electrophoresis. Slides were dried and incubated with CYGEEN
which stains nucleic acids. This staining allowed for visualization using the Olympus BX51
microscope.
2.8.2 Alkaline comet assay
For the alkaline comet assay, Ku70 WT and S155D expressing MEFs were compared to WT
expressing MEFs treated with a range of irradiation doses (1-10 Gy). The cells suspended
in PBS were mixed with 1% agarose and mounted on slides that were precoated with 0.6%
agarose. The rest of the procedure was carried out in the dark. The cells suspended in agarose
were lysed in Lysis Buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris, 1% DMSO, 1% Triton X-
100, pH 10 (NaOH)) for 1 h at 4oC. Slides were then washed 3 times in cold water, incubated
for 45 minutes in alkaline electrophoresis buffer (1 mM EDTA, 50 mM NaOH, 1% DMSO),
and subsequently electrophoresed for 10 minutes at 18 V. Next, the slides were neutralized in
0.4 M Tris buffer (pH 7.0) for 30 minutes at 4oC. Finally the DNA from the cells was stained
with CYGREEN solution allowing for comets to be visualized and analyzed using the Olympus
BX51 microscope.
2.8.3 Comet assay analysis
Once images were taken, the mean tail moment of comets were measured using the Open-
Comet plugin for ImageJ software. The mean tail moment was taken for at least 200 cells
per experimental treatment, was averaged, and was normalized to the mean tail moment of the
untreated WT cells for that experiment.
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2.9 Proximity ligation assay
Proximity ligation assay (PLA) was done for the co-localization of Ku70 and Aurora B in
MEFs stably infected with Ku70 WT, Ku70 S155D, or empty vector (KO). Cells were seeded
the night before on coverslips that had a hydrophobic circle around the outer edge. Cells were
fixed, permeabilized, and blocked as described in the Immunofluorescence Assay section. They
were then incubated overnight at 4oC with primary antibodies mouse anti-Ku70 (N3H10, Santa
Cruz) and rabbit anti-Aurora B (H-75, Santa Cruz). After removal of primary antibodies and
washing in PBS, the cells were incubated with PLA probes: anti-mouse minus and anti-rabbit
plus (Sigma-Aldrich). The ligation and amplification steps were then completed as described
by the manufacturer (Duolink Kit, Sigma-Aldrich). Coverslips were briefly dried and mounted
using DAPI-mounting medium. Images were acquired and prepared as described in the Im-
munofluorescence Assay section. The PLA signal was quantified using ImageJ to calculate
image intensity and this was divided by the number of cells in each image. This value was then
normalized to the PLA signal of the Ku70 KO cells.
2.10 Bacterial protein expression
Ku70 WT and S155D vWA domains were expressed in Escherichia coli (E. coli) cells for
later testing for inhibition of Aurora B. The vWA domains in pET-28-a were transformed into
chemically competent BL23(DE3) E. coli cells. Bacteria were cultured at 37oC. Transformants
were used to innoculate a 2 mL Lysogeny broth (LB) overnight culture, which in turn was
used to spike a 200 mL LB day culture. After 2-3 hours, when the culture reached an optical
density (600 nm) of approximately 0.5, protein expression was induced with 1 mM of Isopropyl
β-D-1-thiogalactopyranoside (IPTG) and cultures were grown for an additional 1.5 hours. A
brief centrifugation was used to harvest a cell pellet, which was frozen and then lysed using
sonication in Lysis Buffer (10 mM KCl, 25 mM HEPES pH 7.4, 2 mM EDTA, 20% glycerol,
and 0.1% NP-40 with inhibitors added as in Whole Cell Extracts). Finally, the cell debris and
soluble protein fractions were separated by centrifugation, and protein expression of each vWA
domain was checked and quantified by SDS-PAGE analysis before being added to kinase assay
reactions.
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2.11 Aurora B kinase assay
Immunoprecipitated Aurora B on magnetic beads was diluted in Kinase buffer (20 mM Tris-
HCl, 20 mM KCl, 20 mM MgCl2, 100 mM ATP (New England Biolabs, Ipswich Massachusetts,
USA), 0.4 mM DTT) and divided into 7 aliquots. One aliquot remained as a control, to the other
6 aliquots increasing amounts of bacterially-expressed T7-tagged Ku70 S155D or Ku70 WT
vWA domain ( 1, 5, and 10 ng ) were added. These were incubated for 30 minutes at 4oC,
following which 1 µg of Histone H3 (New England Biolabs) was added and the solution was
incubated for an additional 30 minutes at 37oC. Finally, SDS loading dye was added to samples
and they were analyzed by western blot (see above) with antibodies against Aurora B, T7-tag,
and phosphorylated Histone H3.
2.12 Statistical analysis
Bar-graph results are represented with standard error of the mean (SEM) error bars. Calcu-
lations of error bars and T-tests for significance were performed using GraphPad (GraphPad
Software, Inc., La Jolla, California, USA). Results were considered significant if analysis by
t-test resulted in a p-value less than 0.05.
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3.1 Ku70 S155D expressing cells have low level DNA damage
similar to that of WT
The research leading up to this work showed the presence of a DNA damage response upon
the expression of Ku70 S155D [91]. It was suggested that this response occurred as the re-
sult of the mutant mimicking Ku phosphorylation and activating a DDR signalling pathway.
However, although improbable because of Ku’s well characterized DNA repair function, it was
also possible that this DDR was activated as a response to actual DNA breaks induced by the
Ku70 S155D expression. To test whether Ku70 S155D expression induces DNA damage, I
expressed Ku70 S155D and Ku70 WT in Ku70−/− MEFs using a retroviral infection system,
as previously described [90], and tested for DNA damage with comet assays (Ku70 WT and
S155D re-expression is demonstrated in Appendix C.1). Quantification of DNA damage was
done using both alkaline and neutral comet assays which assess different types of DNA breaks
and display different levels of sensitivity for DNA breaks.
Briefly, cells that were suspended in low melting point agarose were lysed then treated with
neutral or alkaline conditions and an electric current was applied. In this assay, the applied
electric current causes DNA to move out of the lysed cell and through the agarose gel at a
speed inversely correlated with it’s size. Small and medium sized DNA fragments are present
if DNA damage occurred, otherwise the DNA remains as intact chromosomes. Therefore, in
the presence of DNA damage, small and medium sized DNA fragments migrate out of the cell
and into the agarose gel, whereas intact chromosomal DNA will remain within the cell nucleus.
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When the DNA is subsequently stained, a comet-like tail is visible protruding from each cell
nucleus. This effect is seen in the IR (and H2O2) controls for each comet assay type (Figure
3.1).
Both neutral and alkaline comet assays were performed because each has it’s own strengths.
The alkaline comet assay is performed under denaturing conditions, is highly sensitive, and
is used to quantify the total DNA damage (single and double strand breaks and alkali-labile
sites)[116]. The neutral comet assay is more specific to DNA double strand breaks, as the
neutral conditions are not conducive of separating the two DNA strands, but this also means
that it is less sensitive at low levels of DNA breaks [116].
The level of endogenous DNA damage in the Ku70 S155D expressing MEFs, quantified
using tail moment, was comparable to that of WT Ku70 expressing MEFs in both comet assay
types (Figure 3.1). Both Ku70 WT and S155D expressing MEFs had little to no DNA tail
suggesting that there was little to no DNA damage. There was no significant difference in the
mean comet tail moment and therefore in the measured DNA damage between the Ku70 WT
and S155D cells. The endogenous DNA damage levels of Ku70 WT and S155D expressing
MEFs were also compared to cells treated with exogenous DNA damaging agents including
irradiation and hydrogen peroxide treatment as positive controls for the experiment (Figure
3.1). In the alkaline comet assay, increasing amounts of DNA damage were induced through
irradiation over a range of 1-10 Gy, while for the neutral assay, 40 Gy and H2O2 were the
positive control treatments. Irradiation has previously been shown to be linearly correlated
with induction of DNA DSBs [18, 117]. Previous work has demonstrated that approximately
20-40 DNA DSBs are induced per cell for each 1 Gy of iraditaion dose [18, 118, 117, 119].
These controls demonstrate that upon treatment with a DNA damaging agent the comet assay
is able to detect breakage, and that this breakage is relative to the treatment dose (Figure 3.1).
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Figure 3.1: Alkaline and Neutral comet assays comparing endogenous DNA damage in Ku70
WT and S155D expressing MEFs. Untreated Ku70 WT and Ku70 S155D expressing MEFs,
Ku70 WT expressing MEFs irradiated with 1 to 10 or 40 Gy respectively, and Ku70 WT MEFs
treated with 100 µM hydrogen peroxide for 30 minutes were diluted and suspended in agarose
gel on slides. Following lysis under alkaline or neutral conditions the slides were subjected to
electrophoresis and stained with CYGREEN. Representative images (top) show DNA damage
and corresponding migration. Scale bars, 10 µm. Mean tail moment was quantified for at least
100 comets using OpenComet, and mean tail moment was normalized to Ku70 WT expressing
MEFs for each replicate. Normalized tail moment is shown with error bars indicating SEM
(n=3).
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3.2 Ku70 mutants heterodimerize with Ku80
In addition to testing for induction of DNA breaks upon expression of the Ku70 S155D mutant,
we tested for the ability of the Ku70 S155D and S155A mutants to heterodimerize with Ku80.
Heterodimerization of Ku70 and 80 is important in creating a dimer capable of binding to
DNA DSBs. While this heterodimerization may not be necessary for the activation of the
DDR, heterodimerization would support that the mutant Ku70s could still function in repair.
The S155 residue is located within the vWA domain of Ku70, which is not expected to
be involved in the interaction with Ku80. However, in order to prove that the Ku70 mutants
were still able to form heterodimers, Ku80 was immunoprecipitated from Phoenix-AMPHO
cells that were either untransfected or transiently transfected with HA-tagged full-length (FL)
Ku70 WT, S155A, or S155D. Immunoprecipitates were analyzed by western blot using an-
tibodies against Ku80 and HA-tag. The use of the HA-tagged Ku70 was necessary to de-
tect co-immunoprecipitation of transfected Ku70 and not the endogenous WT Ku70 found in
Phoenix-AMPHO cells.
The results show that HA-FL Ku70 WT, HA-FL Ku70 S155A, and HA-FL Ku70 S155D
all co-immunoprecipitate with Ku80 (Figure 3.2). This confirms that mutation of the S155
residue does not disrupt heterodimerization of Ku70 with Ku80, and specifically demonstrates
that the over-expressed, transfected HA-Ku70s are capable of replacing endogenous Ku70 in
the heterodimer.
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Figure 3.2: Co-immunoprecipitation of Ku70 WT and mutants with Ku80. Ku80 was immuno-
precipitated from Phoenix-AMPHO cells that were untransfected or transfected with Ku70 WT,
S155A, or S155D, each with an HA-tag. The western blot was prepared using primary anti-
bodies against Ku80 and HA-tag. WT Ku70 and both mutant Ku70s co-immunoprecipitated
with Ku80. (n=3).
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3.3 Aurora B co-immunoprecipitates with Ku70 following
IR treatment
Previous work identified Aurora B as a factor interacting with the Ku70 S155D mutant [91].
Since Ku70 S155D is hypothesized to mimic Ku70 phosphorylation in response to DNA dam-
age, we set out to test for an association between WT Ku70 and Aurora B following DNA
damage induced by X-ray irradiation. Ku70 was immunoprecipitated from Ku70−/− MEFs in-
fected with WT Ku70 or empty pMSCV vector that were untreated or irradiated with 40 Gy.
Immunoprecipitates were analysed by western blot with antibodies against Ku70 and Aurora
B.
Aurora B co-immunoprecipitated with Ku70 from irradiated WT Ku70 expressing MEFs
but not from unirradiated MEFs (Figure 3.3). This data supports that the previously charac-
terized phosphorylation event at S155 on Ku70, which occurs in response to irradiation and is
mimicked by Ku70 S155D, mediates the association of Ku70 with Aurora B.
Similarly, Ku70 was immunoprecipitated from nuclear extracts collected from HeLa cells
that were either untreated, or irradiated with 40 Gy. Mouse IgG was used as a control on Hela
extracts. Once again, Aurora B co-immunoprecipitated only with Ku70 from irradiated Hela
extracts demonstrating that this association occurs in both mouse and human cells (Figure 3.3).
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Figure 3.3: Aurora B co-immunoprecipitates with Ku70 after DNA damage. (A) Ku70−/−
MEFs stably expressing Ku70 WT (WT) or infected with empty vector (KO) were untreated
or subjected to 40 Gy of IR treatment and extracts were prepared after 30 min incubation.
Immunoprecipitation was performed with a Ku70 antibody and immunoprecipitates were an-
alyzed by western blot with antibodies against Ku70 and Aurora B. (n=3). (B) The same
protocol was used on HeLa cells, with an additional control using mouse IgG. (n=2).
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3.4 Ku70 S155D and Aurora B co-localize by PLA in situ
In addition to demonstrating the in vitro association of endogenous Ku70 and Aurora B fol-
lowing DNA damage induction using co-immunoprecipitation, we wanted to demonstrate the
in situ co-localization of the phosphomimetic Ku70 (S155D) with Aurora B. This experiment
was conducted using proximity ligation assay (PLA). The co-localization of Aurora B and
Ku70 was assayed in Ku70−/− MEFs re-expressing Ku70 S155D or WT and in Ku70−/− MEFs
containing pMSCV empty vector (KO). Specifically, this assay involved incubating fixed, per-
meabilized, and blocked cells on coverslips with mouse anti-Ku70 and rabbit anti-Aurora B
primary antibodies. The cells were then washed and incubated with PLA probes against rabbit
and mouse, plus and minus respectively, and treated with ligation and amplification mix from
the Duolink kit.
In this assay, if the plus and minus PLA probes are within 40 nm of each other their DNA
tails are ligated together to form a circular template which is then amplified through rolling
circle amplification (Figure 3.3) [120]. The amplification mixture also contains fluorescently
labelled oligonucleotides which are complimentary to the DNA tail of the PLA probe. Thus,
following rolling circle amplification will the fluorescent probe will bind to the amplified DNA
product. As a result of this process the co-localization of Ku70 and Aurora B is seen as small
green dots within cells under a fluorescent microscope’s fluorescein isothiocyanate (FITC)
filter. In this experiment Ku70 KO MEFs were used as a negative control. In the absence of
Ku70 the Ku70 antibody should not bind within the cell, while the Aurora B antibody will bind
to endogenous Aurora B. Therefore, only one PLA probe will bind while the other is washed
away and as a result there should be not be PLA activity.
The results show the presence of green dots within the Ku70 S155D expressing MEFs but
not in Ku70 WT or Ku70 KO MEFs (Figure 3.5). This suggests that Ku70 and Aurora B co-
localize in Ku70 S155D expressing MEFs and that this mutation mediates the interaction. To
quantify these data, the overall intensity of each image containing PLA signal was measured
using ImageJ and this value was then divided by the total number of cells in the image to give a
quantitative PLA signal value. This was done for at least 150 cells for each replicate. The PLA
signal value for Ku70 WT and S155D cells was then normalized to that of KO cells (Figure
3.5). Based on this PLA signal value, Ku70 and Aurora B were found to co-localize in cells
expressing Ku70 S155D significantly more than in cells expressing WT Ku70 or in Ku70 KO
MEFs (Figure 3.5).
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Figure 3.4: Overview of Proximity Ligation Assay (PLA). Antibodies generated in two dif-
ferent species against two proteins of interest are added to cells fixed on coverslips. In this
experiment Ku70 and Aurora B (Aur B) primary antibodies were used. Species specific PLA
probes are added and if the original proteins are within approximately 40 nm their DNA tails
are ligated. Rolling circle amplification is then carried out and a fluorescently tagged oligonu-
cleotide probe binds to the amplified DNA. The fluorescent tag can be seen using fluorescent
microscopy as green green dots representing co-localization.
Chapter 3. Results 43
A KO WT S155D
PLA
DAPI
WT S155D
PL
A 
Si
gn
al
*
B
Figure 3.5: Interaction of Aurora B and Ku70 S155D using Proximity Ligation Assay (PLA).
(A) Representative images for PLA co-localization of Aurora B and Ku70 in situ. Ku70−/−
MEFs re-expressing Ku70 WT or S155D or infected with empty vector (KO) were fixed on
coverslips and incubated with antibodies against Ku70 and Aurora B and processed for PLA
analysis. With this assay, co-localization of Ku70 and Aurora B creates green dots and nuclei
are stained with DAPI in blue. Images were taken with the 40x objective and scale bars rep-
resent 10 µm. (B) The PLA signal was quantified using ImageJ to calculate intensity per cell,
and this was normalized to the PLA signal in the Ku70 KO cells. Quantification is shown as
the average of three experiments with error bars indicating SEM. (*p<0.05, n=3).
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3.5 Ku70 S155D vWA domain inhibits Aurora B-dependent
Histone H3 phosphorylation
Since Ku70 S155D interacts with Aurora B in situ we sought to determine whether this plays
a role in the Ku70 S155D-dependent activation of the DDR. Through the use of an in vitro
kinase assay, previous work demonstrated that Aurora B imunoprecipitated from Ku70 S155D
expressing MEFs has reduced kinase activity [91], suggesting that Ku70 S155D expression
leads to Aurora B inhibition. However, this inhibition of Aurora B had not been shown to be
a direct effect of Ku70 S155D expression. Since Aurora B chemical inhibition demonstrated
similar effects as expression of Ku70 S155D, this inhibition merited further investigation. In-
terestingly, the expression of the Ku70 vWA domain alone was previously shown to efficiently
activate a DDR, sugesting that that the DDR activation following Ku70 S155D expression is
not dependent on DNA binding capabilities or heterodimerization with Ku80 [91].
We therefore wanted to test whether the Ku70 S155D vWA domain was sufficient to inhibit
Aurora B kinase activity, which in turn could suggest a role for this inhibition in the activa-
tion of the DDR seen upon Ku70 S155D vWA domain expression. To this end, Aurora B was
immunoprecipitated from Ku70 WT expressing MEFs and was divided equally into seven frac-
tions. One fraction was left as a control, and to the others, increasing amounts of bacterially
expressed T7-tagged Ku70 S155D or WT vWA domains were incubated with the immunopre-
cipitated Aurora B. These fractions were then subjected to an in vitro Aurora B kinase assay
for purified Histone H3 phosphorylation.
Histone H3 phosphorylation was readily observed in the control, demonstrating robust ki-
nase activity of immunoprecipitated Aurora B. Addition of the WT Ku70 vWA domain had
a small effect in the reduction of Histone H3 phosphorylation but upon addition of the Ku70
S155D vWA domain the amount of phosphorylated Histone H3 decreased further. Quantifica-
tion of the phospho-Histone H3 signal for four experiments demonstrated that while the amount
of Histone H3 phosphorylation was slightly reduced non-specifically upon the addition of the
WT vWA domain, there was a significantly greater reduction in the phosphorylation of Histone
H3 with the addition of increased amounts of the Ku70 S155D vWA domain relative to Ku70
WT vWA addition (Figure 3.6). This reduction in phospho-Histone H3 supports the idea that
the Ku70 vWA domain is sufficient to inhibit Aurora B when the S155 position is mutated to
S155D.
Chapter 3. Results 45
Histone H3 
pSer10
Aurora B
T7-Ku70
vWA
S155D vWA
IP: Aurora B
48 -
35 -
17 -
WT vWA
WT vWAS155D vWA
*
*
Re
la
�v
e 
in
te
ns
ity
A
B
R
el
at
iv
e 
pH
is
to
ne
H
3
in
te
ns
ity
 
Figure 3.6: Aurora B kinase activity assay in the presence of increasing amounts of Ku70
S155D or WT vWA domain. Ku70 WT-expressing MEF nuclear extracts were immunopre-
cipitated with an Aurora B antibody. The immunoprecipitates were incubated with 0, 1, 5,
or 10 ng of bacterially expressed, T7-tagged Ku70 S155D or WT vWA domains. A) Aurora
B kinase activity was assessed using an in vitro kinase assay for Histone H3 phosphorylation
and analyzed by western blot with antibodies to phospho-H3S10, T7 tag, and Aurora B. B)
Phospho-H3S10 western blot signal was quantified relative to immunoprecipitated Aurora B
and is shown as an average with error bars indicating SEM. (*p<0.05, n=4).
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3.6 Treatment of Ku70 S155D expressing cells with an Au-
rora B inhibitor does not increase the activation of DNA
damage response markers
Ku70 S155D expression causes the activation of the DDR and the inhibition of Aurora B, and
the chemical inhibition of Aurora B results in similar effects as Ku70 S155D expression [91].
Therefore, it was postulated that the expression of Ku70 S155D could lead to the inhibition of
Aurora B, which in turn causes DDR activation. However, a causal relationship between the
inhibition of Aurora B and the activation of the DDR was not established. To test whether the
expression of Ku70 S155D and the chemical inhibition of Aurora B phenotypes are associated,
we assayed for the additive effect of treating Ku70 S155D expressing MEFs with an Aurora
B inhibitor. Ku70−/− MEFs re-expressing Ku70 WT or S155D, were seeded on coverslips
and treated with 20 nM of the Aurora B inhibitor AZD-1152 or DMSO vehicle control for 24
hours. Cell were prepared for immunofluorescence assay using an antibody against γH2AX
and the nucleus was stained with DAPI. The signal was quantified as the percentage of cells
with greater than 5 foci for at least 100 cells, averaged over three replicates for each treatment.
For this experiment we had two possible expected outcomes: If the DDR effects of Ku70
S155D expression were due to Aurora B inhibition, then further inhibition of Aurora B would
have little to no additional effects; however, if Ku70 S155D had effects on the DDR in addition
to inhibiting Aurora B, then subsequent treatment with an Aurora B inhibitor would increase
the DDR activation.
As expected, the percentage of cells with more than 5 γH2AX foci was significantly in-
creased when WT Ku70 expressing cells were treated with the Aurora B inhibitor (Figure 3.7).
Conversely, while the percentage of cells with more than 5 foci in untreated S155D cells was
significantly increased relative to untreated WT cells, additional treatment of the S155D ex-
pressing MEFs with the Aurora B inhibitor did not further increase the response. Therefore,
expression of Ku70 S155D leads to the phosphorylation of the DNA damage marker H2AX,
and the phosphorylation of this DNA damage response marker is not significantly increased
upon treatment with an Aurora B kinase inhibitor. This suggests that the effects are sequential
and that the expression of Ku70 S155D acts to inhibit Aurora B, which in turn leads to the
activation of the DDR.
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Figure 3.7: Aurora B chemical inhibition does not increase the DNA damage response in Ku70
S155D expressing MEFs. Ku70 WT and S155D expressing MEFs were seeded on coverslips
and treated with 20 nM of the Aurora B inhibitor AZD-1152 (Aur B i) or DMSO vehicle control
for 24 hours. Cells were then prepared for immunofluorescence analysis using an antibody
against γH2AX and DAPI stain. (A) Representative photos were taken at 40x magnification
and the scale bar represents 20 µm. (B) The γH2AX signal was quantified for at least 100
cells by counting the number of cell with more than 5 foci and dividing by the total number of
cells to determine a percentage of cells with >5 foci per cell. There is no significant difference
between the signal in Ku70 S155D expressing cells untreated or treated with the Aurora B
inhibitor. Error bars represent SEM (n=3).
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3.7 Establishment of a Ku70 inducible system
The expression of either Ku70 S155D or the Ku70 S155D vWA domain was demonstrated to
activate the DNA damage response and cell cycle arrest [91]. However the system employed
involves the selection of Ku70 S155D expressing cells for several days. This system does
not allow for the detection or analysis of early events stimulated upon Ku70 S155D expres-
sion. Thus, we sought to establish an inducible system to investigate early cellular responses to
Ku70 S155D expression. Tetracycline-repressible (Tet-Off) Ku70 WT and S155D constructs
were created and tested. Full-length Ku70 WT and S155D were cloned into the pBIG2r vector.
This vector contains a tetO element which allows for repression under tetracycline, a CMV
promoter for the inserted DNA of interest, and a TK element for the tetracycline repression
component [113]. Therefore, when maintained under tetracycline Ku70 should not be ex-
pressed. Addtitionally, this vector contains a selectable marker which confers resistance to
hygromycin B. The pBIG2r vector containing Ku70 WT or S155D was transfected into Ku70
knockout MEFs and transfected cells were selected with hygromycin B to generate stable cell
lines. These cell lines were maintained under tetracycline to repress Ku70 expression.
To demonstrate functionality and utility of this system, cells maintained under tetracycline
were compared with those that had been released from tetracycline control for 2-24 hours.
Before the removal of tetracycline there was consistently little to no Ku70 expression visible
by western blot; while 24 h after tetracyclin removal, Ku70 was expressed from both the Ku70
WT and S155D pBIG2r constructs (Figure 3.8). Additonally, upon release from tetracycline
control the amount of Ku70 in the cells gradually increased over time in both the pBIG2r WT
and S155D cells (Figure 3.8). This expression was also analyzed by immunofluorescence with
a Ku70 antibody. At 0 h, both S155D and WT pBIG2r containing cells had little to no Ku70
signal, while at 24h a portion of cells showed Ku70 expression (Figure 3.8). In this experiment,
cells were additionally incubated with a γH2AX antibody so that the activation of the DDR in
response to Ku70 WT or S155D expression could be visualized. The percentage of Ku70
expressing cells that contained more that 5 γH2AX foci was calculated for the Ku70 WT and
S155D pBIG2r cells at the 8 h and 24 h post removal of tetracycline. It appears that at both
time points the percentage of Ku70 expressing cells that contained more that 5 γH2AX foci
was greater in the Ku70 S155D pBIG2r cells than in the WT equivalent (Figure 3.8). These
results demonstrate that a Tet-Off, inducible system for Ku70 WT and S155D was established
and that in this system the activation of the DDR is consistent with previous studies using
infected Ku70 WT and S155D [91].
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Figure 3.8: Establishment of an inducible Ku70 WT and S155D expression system. Ku70
knockout MEFs were transfected with, and stably selected for, pBIG2r Tet-Off constructs of
Ku70 WT and S155D. A) Levels of Ku70 expression were analyzed by western blot for both
cells maintained under tetracycline control (0 h) or 24 h after the removal of tetracycline (24
h). Vinculin is included as a loading control. B) A gradual onset of Ku70 S155D expression
upon the removal of tetracycline repression. Ku70 S155D is shown and the pattern for WT was
similar. C) The expression of Ku70 WT and S155D was also analyzed by immunofluorescence
for Ku70 with DAPI as a nuclear marker. Representative images of Ku70 expression in a
subset of the the cells that have been removed from tetracycline control (24 h) but not in those
maintained under tetracycline control (0 h). Images were taken with the 20x objective and
scale bars represent 40 µm. D) Quantification of the the percentage of Ku70 expressing cells
that also showed more than 5 γH2AX foci. This analysis was done for WT and S155D pBIG2r
cells that had been removed from tetracycline control for 8 and 24 h. At least 50 cells were
counted per replicate. The percentage of Ku70 expressing cells that had more than 5 γH2AX
foci was greater in the Ku70 S155D pBIG2r cells than in the WT Ku70 pBIG2r cells at both
the 8 and 24 h time points. Data for 2 replicates of the experiment (red and blue) are shown.
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The aim of this study was to advance our understanding of the mechanisms through which
Ku70 S155D functions to activate the DDR. We hypothesized that Ku70 S155D mimics phos-
phorylation of Ku70 in response to damage, and that Ku70 S155D is able to inhibit Aurora B
leading to a sustained activation of the DDR and cell cycle arrest through activation of DDR
signalling. The results suggest that the Ku70 S155D vWA domain is able to activate the DDR
independent of DNA damage, and that this may be due to the inhibition of Aurora B.
4.1 Summary of results
First, the expression of Ku70 S155D does not generate endogenous DNA damage in a cell.
In addition, S155A and S155D mutations within the vWA domain of Ku70 do not affect the
heterodimerization of Ku70 with Ku80. We also demonstrated an association of Aurora B with
WT Ku70 following IR, a condition which has previously been demonstrated to induce Ku70
S155 phosphorylation. Additionally, the association of Ku70 S155D with Aurora B in situ was
demonstrated using PLA. Further, the Ku70 S155D vWA domain was shown to be sufficient
to inhibit Aurora B in an in vitro kinase assay. Finally, the chemical inhibition of Aurora B
in Ku70 S155D expressing cells showed no significant increase in the activation of the DDR
marker γH2AX. The results of this work suggest that Ku70 S155D and phosphorylated Ku70
associate with and inhibit Aurora B, and that this inhibition is not dependent on DNA binding
or heterodimerization as the Ku70 S155D vWA domain was sufficient to inhibit Aurora B. Ad-
ditionally, as the inhibition of Aurora B in Ku70 S155D expressing cells did not increase DDR
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markers, Ku70 S155D-dependent DDR activation may function through Aurora B inhibition.
The induction of the DNA damage response upon the expression of Ku70 S155D is a novel
discovery for the function of Ku in signalling following DNA damage [91]. In order to demon-
strate that this activation was not induced by DNA breaks caused by the expression of Ku70
S155D, comet assays for DNA damage were performed. The results of both the neutral and
alkaline comet assays demonstrate that there is no significant difference in the level of DNA
damage between WT and Ku70 S155D expressing cells. This result supports the notion that the
DNA damage response activation in response to Ku70 S155D expression is not due to the cre-
ation of DNA damage but instead is an activation of signalling by the phosphomimetic mutant.
This result is not surprising, as it seems unlikely that a single amino acid substitution would
alter the function of Ku70 from a DNA repair protein to a DNA damage creating agent. Next,
we demonstrated that the S155D and S155A mutant Ku70 proteins co-immunoprecipitate with
Ku80, suggesting that the heterodimer can form. The heterodimerization of Ku70 and Ku80
has been previously been characterized to occur through the core domains of these two subunits
[61]. This is consistent with our results which demonstrate that a single amino acid mutation
at the Ku70 155 site within the Ku70 vWA domain does not impact heterodimerization with
Ku80. Therefore the function of this heterodimer in cNHEJ repair is likely not disrputed. This
result is consistent with previous data which demonstrated that a S155A/D156A double mu-
tation does not affect the DNA repair function of Ku70 [90]. Altogether, these experiments
demonstrate that the Ku70 S155D mutation does not interrupt the Ku70/Ku80 heterodimer or
impact the level of endogenous DNA damage within the cell. This work is consistent with
Fell and Schild-Poulter’s suggestion that Ku70 S155D induces the DDR through activation of
a signalling pathway [90].
Aurora B was previously identified in a screen to identify proteins which interact with Ku70
S155D [91]. This association was confirmed by Aurora B co-immunoprecipitation with Ku70
S155D in vitro [91]. As an extension of this work, the results in this study demonstrate that
Aurora B co-immunoprecipitates with Ku70 from irradiated cells, but not from unirradiated
control cells. This co-immunoprecipitation of Aurora B and Ku70 following irradiation was
observed in both MEF and HeLa cells, demonstratng conservation between mamalian species.
As the Ku70 S155 position has been demonstrated to be phosphorylated in response to irradi-
ation [91], these results suggest that Aurora B associates with phosphoS155 Ku70. In order
to demonstrate this association of Aurora B with Ku70 in situ, a proximity ligation assay was
employed in cells expressing either Ku70 WT or the phosphomimetic Ku70 S155D. Aurora B
was found to co-localize with Ku70 in cells expressing the S155D mutant but not with Ku70
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in cells expressing Ku70 WT. This once again supports that Aurora B associates with Ku70
S155D and phosphorylated Ku70, but also demonstrates that the association occurs in situ.
Additionally, the correspondence between the association of Aurora B with Ku70 S155D by
PLA and with phosphorylated Ku70 by co-immunoprecipitation validates further use of the
Ku70 S155D phosphomimetic mutant to study the role of this phosphorylation in the activa-
tion of the DDR.
In addition to demonstrating Aurora B association with Ku70 S155D, the results of in vitro
kinase assay demonstrate that bacterially expressed Ku70 S155D vWA domain is capable of
inhibiting Aurora B kinase activity. The reduction in Histone H3 phosphorylation by Aurora
B in the presence of the Ku70 S155D vWA domain demonstrates an important function of this
phosphomimetic mutation and therefore importance of phosphorylation. This experiment sug-
gests that the vWA domain mediates this inhibition effect, and is sufficient to inhibit Aurora B.
The sufficiency of the vWA domain in inhbition suggests that the heterodimerization and DNA
binding capabilities of Ku70 are not required to inhibit Aurora B. This result is consistent with
previous work by Fell et. al. which demonstrated that the expression of the Ku70 S155D vWA
domain in cells was sufficient to induce the DDR [91]. In fact, the activation of the DDR was
also observed when the Ku70 S155D vWA domain was expressed in cells with endogenous
Ku70, suggesting a dominant effect [91]. Previous investigations revealed that bacterially ex-
pressed Ku70 S155D vWA domain was not sufficient to inhibit recombinant GST-Aurora B in
an in vitro kinase assay, suggesting that the interaction is not direct (Fell and Schild-Poulter,
Unpublished). This suggests that the vWA may interact with other factors associated with Au-
rora B. It is possible that the Ku70 S155D vWA domain interacts with an Aurora B associated
factor and inhibits Aurora B directly, or that this interaction leads to alteration of a complex
and indirectly decreases Aurora B kinase activity. This notion is consistent with previous re-
search which demonstrates that INCENP and other factors are nececessary for full Aurora B
kinase activity [121]. Additionally, Gohard and colleagues demonstrated that interruption of
the INCENP-Aurora B interaction reduces Aurora B kinase activity [121]. Therefore, it is pos-
sible that the Ku70 S155D vWA domain interrupts such an interaction and leads to Aurora B
inhibition. The inhibition of Aurora B by the Ku70 S155D vWA domain, may help explain
how the Ku70 S155D vWA domain is able to activate the DDR response in both cell competent
for Ku70 and cells deficient for Ku70.
The Ku70 S155D vWA inhibition of Aurora B hinted about the mechanism of Ku70 S155D-
dependent activation of the DDR through the inhibition of Aurora B. Since Aurora B chemical
inhibition induces a DDR, and the Ku70 S155D vWA domain inhibits Aurora B and induces a
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DDR, we suggested that Ku70 S155D, or phosphoS155 Ku70, induces DDR activation through
Aurora B inhibition. However, the sequential effect of Ku70 S155D expression leading to
Aurora B inhibition which in turn causes the DDR had not been investigated. This led us to
test for an additive effect of Ku70 S155D expression and the inhibition of Aurora B. Consistent
with results that were previously demonstrated by Fell et. al. (2016), the treatment of WT
Ku70 MEFs with an Aurora B inhibitor resulted in the activation of the DDR, as characterized
by the increase in the number of cells with more than 5 γH2AX foci. A similar activation of
the DDR, and therefore the presence of DDR markers, is also seen in untreated Ku70 S155D
expressing MEFs. However, the treatment of Ku70 S155D expressing MEFs with an Aurora
B inhibitor did not trigger an increase in γH2AX foci relative to untreated Ku70 S155D cells.
There are two possible explanations for this result: First, Aurora B is already inhibited in Ku70
S155D MEFs, so the addition of the Aurora B inhibitor is redundant and does not increase the
activation of the DDR. This explanation is consistent with previous work by Fell et. al. (2016)
which demonstrated that Aurora B immunoprecipitated from Ku70 S155D MEFs is inhibited
in its kinase activity. However, a second explanation of this result that cannot currently be ruled
out is that cell expressing Ku70 S155D already have reached a maximal threshold of γH2AX
activation. Therefore, even though the Aurora B inhibitor may functionally inhibit Aurora B
and activate the DDR, this activation is masked by the DDR activated by Ku70 S155D. These
results suggest that DDR activation through Ku70 S155D expression occurs at least in part
from Aurora B inhibition, but further experimentation will be needed to confirm this.
Finally, a Tet-off system for Ku70 WT and S155D expression was established. The removal
of tetracycline from cells selected to have integrated Ku70 S155D or WT pBIG2r plasmids
triggers the induction of Ku70 expression. The expression of Ku70 WT and S155D in these
cells was demonstrated by western blot and immunofluorescence assay. In both western blot
and immunofluorescence analysis, the expression of the Ku70 S155D appeared to be lower than
its WT counterpart. This could be due to a lower per cell expression, but immunofluorescence
assay demonstrates a lower percentage of cells are expressing Ku70 S155D than in the WT.
The expression of Ku70 S155D is unfavourable to the cells, which may partially explain the
lower proportion of Ku70 S155D expressing cells when compared to the corresponding WT
Ku70 expression. However, WT Ku70 is also not expressed in all cells following tetracycline
removal. It is possible that the expression in these cells may take longer and therefore was
not detected at the 24 h time point and that later analysis would be needed to demonstrate a
larger proportion of WT Ku70 expressing cells. Alternatively, it is possible that these cells
do not contain the WT Ku70 pBIG2r construct and have developed or maintained resistance to
hygromycin selection which allowed for their survival. Future experiments to address this issue
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could include testing MEF sensitivity to hygromycin and increasing the hygromycin selection
concentration following pBIG2r construct transfection. The establishment of this system will
be important for future work into the time line for and mechanism of Ku70 S155D inhibition
of Aurora B leading to activation of cell cycle checkpoints and the DDR (See Future Work).
4.2 Significance of the Ku70 S155D association with and in-
hibition of Aurora B
The Ku70 S155 site has not been previously identified as a site for phosphorylation in pro-
teomic studies [122]. However, this may be due to low level phosphorylation of this position
in response to DNA damage [91].
Our proposed model is that following DNA damage, Ku initiates repair through the recruit-
ment of the repair complex. In the case of successful repair, Ku70 is not phosphorylated at the
S155 amino acid. In the case of repair no Aurora B inhibition occurs. Therefore, signalling
to the DDR is hindered. We propose that in the event of overwhelming DNA damage, Ku70
is recruited to the break but DNA repair cannot be completed. This may occur because Ku is
much more abundant than other members of the cNHEJ. Therefore, in the case of overwhelm-
ing DNA damage, Ku would bind at all DNA breaks but is not able to recruit a functional repair
complex to every DNA break. Alternatively, repair may be slowed by the complexity of the
DNA break, and therefore need increased time for processing. We suggest that in this case
Ku becomes phosphorylated and interacts with the Aurora B complex resulting in Aurora B
inhibition (Figure 4.1). The inhibition of Aurora B is associated with a corresponding increase
in DDR activation and activation of the cell cycle checkpoints. This hypothetical model helps
to explain the low levels of Ku70 S155 phosphorylation as well as the activation of the DDR
response seen upon the expression of Ku70 S155D, which is a stronger and sustained mimic of
the equivalent endogenous phosphorylation.
In addition to demonstrating an interaction of Ku70 S155D and Aurora B, previous work
showed that the expression of Ku70 S155D led to the inhibition of Aurora B, demonstrated us-
ing an in vitro kinase assay [91]. This work also investigated the effect of FLAG-Tagged Ku70
WT and S155D vWA domain expression in Ku70 knockout MEFs and in human IMR-90 cells
which have endogenous Ku70. In both the knockout and endogenous human Ku backgrounds,
the expression of the Ku70 S155D vWA domain led to decreased proliferation and increased
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p21 levels relative to WT Ku70 vWA domain expression [91]. The work in this thesis expands
upon this by demonstrating that the Ku70 S155D vWA domain alone is sufficient to inhibit Au-
rora B in vitro, which helps to explain the dominant effect of the Ku70 S155D vWA domain in
IMR90 cells. This Ku70 S155D vWA-dependent inhibition suggests that the phosphorylation
of the S155 site can induce a signalling response which inhibits Aurora B and activates the
DDR, independent of DNA binding and heterodimerization with Ku80. The role of Aurora B
in the DDR remains to be characterized, but the effects of Aurora B inhibitors in this and other
studies, support that inhibition leads to activation of DDR signalling [91, 95, 109, 110]. How-
ever, we still cannot rule out that the DDR response of Ku70 S155D expression is activated by
mechanisms distinct from Aurora B inhibition.
4.3 Aurora B and the DDR
Aurora B has been previously linked to DDR signalling through interactions with proteins
including: PARP1 and ATM [55, 112]. The DDR-dependent activation of PARP1 was demon-
strated to poly(ADP- ribosyl)ate Aurora B, which results in inhibition of Aurora B kinase
activity [112]. This study additionally demonstrated that induction of DNA damage (through
irradiation or H2O2 treatment) was associated with lower levels of phosphorylated Histone H3
while levels of Aurora B remain constant [112]. The decrease in phosphorylation of Histone
H3 was abrogated in cells deficient for PARP1, which suggests that in response to DNA dam-
age, Aurora B kinase activity is inhibited through PARP1 activity. Aurora B kinase activity was
also previously shown to be inhibited through ATM-dependent phosphorylation of I-2, which
removes inhibition of and therefore activates PP1 [55]. The inhibition of Aurora B in this man-
ner was once again associated with decreased levels of Histone H3 phosphorylation but also
with the induction of the G2/M cell cycle checkpoint [55]. This result was corroborated by
similar research which showed Aurora B inhibition in the presence of active PP1 [123]. The
results of the discussed studies parallel those in this thesis, and demonstrate a role for Aurora
B in DDR signalling.
4.4 Ku70 and the DDR
In concurrence with the work in this thesis, Tomimatsu and colleagues have also documented a
role for Ku in the DDR, outside of its repair function [48]. These authors were interested in the
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Figure 4.1: Revised model for the cells response to DNA damage through Ku70 phosphoryla-
tion. Upon DNA DSB induction Ku70 is recruited to the break. A) In the case of successful
repair we propose that Ku70 S155 does not become phosphorylated and therefore Aurora B
remains active. This means that there is no additional DDR activation or cell cycle arrest.
This is also the case when Ku70 S155A, which cannot be phosphorylated, is expressed. B)
We propose that in the event of overwhelming or complex damage, DNA repair is inefficient
or delayed. In this case Ku70 S155 becomes phosphorylated and interacts with the Aurora B
complex, leading to Aurora B inhibition. This leads to increased DDR activation and cell cycle
arrest. This also occurs when the phosphomimetic Ku70 S155D is expressed.
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possible modulation of ATM and ATR kinases by the Ku heterodimer [48]. They provide evi-
dence that the Ku heterodimer modulates ATM-dependent activation of ATR and that activated
ATR acts to phosphorylate p53 [48]. The phosphorylation of p53 by ATM and ATR is a key
step in the activation of the DDR, specifically in the activation of cell cycle checkpoints and
apoptosis [48]. The authors additionally demonstrate that in both Ku70- and Ku80-deficient
cells, ATR is activated in a ATM-independent way, and that this type of activation leads to the
irregular persistence of p53 phosphorylation following IR [48]. The overall conclusion of this
study is that the Ku heterodimer is necessary for the ATM-dependent activation of ATR. The
work by Tomimatsu and colleagues demonstrates, as this work does, that Ku at DSBs has a
function beyond the recruitment of repair factors and into the modulation of DDR signalling
pathways.
4.5 Ku70 S155, the DDR, and cancer
A number of members of the cNHEJ pathway have been associated with cancer and aging
[124]. Theoretically, the cNHEJ can counteract the efficacy of cancer treatments such as
chemotherapy and radiation therapy which induce DSBs to target cancer cells. However, the
cNHEJ, like most pathways in cancer cells, becomes deregulated and these treatments target
the components of this pathway in cancer cells [11, 13, 124]. Therefore drugs targeting mem-
bers of the cNHEJ, including inhibitors of Ku protein-protein and protein-DNA interactions,
are potential sensitizers to chemotheraputic and radiation treatments [124].
Ku is frequently deregulated for both activity and expression in tumour samples [125, 126,
127, 128]. The Ku70 S155 site specifically has not been identified as a site of mutation in
cancer by the Catalogue of Somatic Mutations in Cancer (COSMIC). The absence of a Ku70
S155D mutation in cancer is not surprising, as the expression of such a Ku70 mutant would
activate the DDR and cause cell cycle arrest, features that are unfavourable to cancer progres-
sion. However, the expression of a S155A Ku70, which could not be phosphorylated and has
an increased growth rate relative to WT Ku70 MEFs, would be a more likely mutation favour-
ing cancer development. Although such a mutation has also not been demonstrated, a D156N
mutation was identified in a lung carcinoma sample (Figure 4.2) [129]. This aspartic acid to
asparagine amino acid change represents a change from a negatively charged side group to an
uncharged but polar side chain of similar size and structure. This alteration of charge could
interrupt the phosphorylation of the S155 site. Specifically, the SXXQ (a.a. 155-158) con-
sensus sequence has been identified as a consensus sequence for kinases such as ATM and
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DNA-PK [122]. The charge alteration in this region may affect the ability of the kinase respon-
sible for phosphorylation to recognize the sequence and phosphorylate Ku70. Therefore, the
D156N mutation in the lung carcinoma sample may suppress the Ku70 S155 phosphorylation-
dependent activation of the DDR that has been described in this work.
Additionally, there are three other mutations recorded in the COSMIC database that occur
just a few amino acids before the S155 site (Figure 4.2). These V149I, A151V, and L153F
mutations are not directly part of the predicted SXXQ consensus sequence for Ku70 phos-
phorylation, but it is still possible that they could alter the probability of the S155 becoming
phosphorylated because of their proximity to the site.
While the S155D and S155A mutations of interest in this work have not been identified in
cancer, they may still have a role to play in our understanding of, and maybe even in treatment
of cancer. For example, the ability of the Ku70 S155D vWA domain to inhibit Aurora B in vitro
and to have a dominant effect over endogenous Ku70 in the activation of the DDR are promising
results. They suggest that the expression of a Ku70 S155D peptide or the manipulation of
the endogenous Ku70 S155 site could be used to activate the DDR in cancer cells and cause
cell cycle arrest or even apoptosis. This treatment could be use in combination with other
compounds to therapeutically suppress tumour growth.
4.6 Future directions
While this research has identified a novel role for the phosphorylation of the Ku70 vWA domain
in inhibiting Aurora B and activating the DDR, there is still much to be characterized with
regards to this pathway.
A first major question to be addressed in the future is: What phosphorylates Ku70 following
the induction of DNA DSBs? This question has been of ongoing interest but has proven difficult
to determine without a specific and functional phospho-S155 Ku70 antibody. The DDR is a
complex network of kinases, and therefore there are many candidate kinases which could be
responsible for Ku70 S155 phosphorylation. However, the S155 site is contained in a SDVQ
sequence which matches a loose SXXQ consensus sequence which has been demonstrated to be
phosphorylated by ATM and DNA-PK [122]. These two kinases are therefore likely candidates
for Ku70 S155 phosphorylation. With a p155 Ku70 specific antibody, the phosphorylation of
the S155 Ku70 site could be monitored and quantified following induction of DNA damage
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Figure 4.2: Substitution mutations near the S155 site recorded in cancers by the COSMIC
database. There is a cluster of mutations proximal to the S155 amino acid of the Ku70 vWA
domain which have been identified within tumour samples. Mutations between amino acids
140-160 of the Ku70 vWA domain as documented in the COSMIC database. This image was
derived from information in the COSMIC database [129].
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in the presence of an ATM or DNA-PK inhibitor, or in competent/deficient cell line pairs for
these kinases. Additionally, to specifically determine the kinase responsible, these experiments
could be paired with in vitro assays for Ku70 S155 phosphorylation.
In addition to possibly being the kinase responsible for Ku70 phosphorylation, the role
for ATM in the Ku70 S155D-dependent inhibition of Aurora B and activation of the DDR is
of interest. Previous work demonstrated that ATM is phosphorylated at S1981 in response
to Ku70 S155D expression [91]. This phosphorylation is well documented as a key event in
the activation of ATM, which in turn acts as the apex kinase in the DDR [46, 49]. The DDR
is an extensive network, so although possible that Ku70 phosphorylation (or Ku70 S155D
expression) activates an alternate pathway with the same endpoint and markers, it it likely that
this signalling converges into the ATM dependent signalling pathway. It would therefore be
interesting to further study this work in an ATM competent/deficient cell line pair in order to
determine if the DDR activated by Ku70 S155D expression is dependent on ATM.
A second major gap is the lack of understanding of how Ku70 inhibits Aurora B and in-
duces DDR signalling. Future work could investigate other proteins that associate with Ku70
S155D and Aurora B to determine mediators of the interaction and inhibition. One method
to identify interactors is BioID, a method which uses a promiscuous biotin ligase-bait fusion
protein, which will biotinylate proteins that exist in proximity to the bait protein [130]. In the
future, Ku70 WT-biotin ligase and Ku70 S155D-biotin ligase fusion protein could be gener-
ated and independently infected into Ku70−/− MEFs. In the cell the promiscuous biotin ligase
would biotinylate proteins in proximity to the Ku fusions. A pull down for biotinylated proteins
would enrich for proteins that are tagged with biotin. These proteins could then be identified
through mass spectrometry and the list of proteins associated with Ku70 WT and S155D com-
pared. Proteins that preferentially associate with Ku70 S155D could further be validated for
their role in the Ku70 S155D-dependent inhibition of Aurora B and activation of the DDR.
Likely candidates include other members of the chromosomal passenger complex or key ki-
nases of the DDR. It was previously demonstrated that ATM and ATF2 are phosphorylated,
and therefore activated in Ku70 S155D cells [90, 91]. Both of these proteins signal for cell cy-
cle arrest through the DDR. Additionally, p21, a key effector of the DDR, was demonstrated to
be upregulated [91]. These results suggest that ATM and ATF2 regulation play a role in Ku70
S155D dependent activation of the DDR, and that they may therefore be identified in a BioID
screen. In further studies, the mechanism of the Aurora B inhibition leading to activation of
the DDR through associated proteins could be studied using a similar system. Knowledge of
other proteins which interact with Ku70 S155D and Aurora B may be vital to developing an
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understanding of the mechanism of Aurora B inhibition by phosphoS155 Ku70 and how this
leads to DDR activation.
Another avenue for future research into the mechanism of DDR activation through Ku70
S155D expression is determining the preliminary response to Ku70 S155D expression. Fell
and colleagues (2016), demonstrated that both a DNA damage response and cell cycle arrest
are induced upon Ku70 S155D expression [91]. However, the activation of the DDR leads to
cell cycle arrest, and cell cycle arrest can lead to activation of the DDR [131, 132]. Therefore,
it remains unclear whether Ku70 S155D expression first leads to DDR or cell cycle arrest. Fu-
ture studies could use the Tet-off Ku70 WT and S155D expression system developed in this
thesis to study the onset of the DDR and cell cycle arrest upon expression of Ku70 WT or
S155D. Specifically, this system in combination with cell cycle synchronization could be used
to determine whether the DDR or cell cycle arrest response of Ku70 S155D expression oc-
curs as the primary effect. Tet-off Ku70 WT and S155D cells chemically arrested in the G1
stage could be removed from tetracycline to allow for Ku70 WT or S155D expression. These
cells could then be analyzed for DNA damage response markers or released from chemically-
induced cell cycle arrest and analyzed for Ku70 S155D-induced cell cycle arrest and DNA
damage markers at time points following release. Such an experiment would aim to deter-
mine if Ku70 S155D-dependent DNA damage markers appear, then cell cycle arrest occurs,
or if Ku70 S155D-dependent cell cycle arrest occurs, then the DDR markers appear, thereby
determining the primary effect of Ku70 S155D expression and Ku70 phosphorylation.
A final interesting avenue for future research is to investigate the ability of the Ku70 S155
site phosphorylation state to regulate cell cycle arrest. In the future, the expression of a Ku70
S155D peptide or the manipulation of the endogenous Ku70 S155 site could be used as a
therapeutic to induce cell cycle arrest and apoptosis in cancer cells.
4.7 Conclusions
The main goal of this work was to determine how phosphorylated Ku70, through experimen-
tation using the phosphomimetic Ku70 S155D, is able to inhibit Aurora B and mediate the
DDR and cell cycle arrest. Work in this thesis demonstrated that substitutions at the Ku70
S155 site do not affect heterodimerization or the endogenous cellular levels of DNA damage.
Additionally, this work characterized the association of Aurora B with phosphorylated Ku70
and Ku70 S155D, and the role of Ku70 S155D in the inhibition of Aurora B. Specifically, the
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Ku70 S155D vWA domain is sufficient to inhibit the activity of immunoprecipitated Aurora B.
Experiments involving Aurora B inhibition in Ku70 S155D expressing cells potentially sug-
gest that Aurora B inhibition by Ku70 S155D leads to the the activation of the DDR. Finally, in
addition to developing our understanding of the Ku70 S155 site role in Aurora B inhibition and
DDR activation, this work has created systems and laid groundwork that will allow for future
research to also further our understanding of this novel signalling pathway.
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Appendix A
List of Primers
Table A.1: List of Primers, their use, and the 5’ to 3’ nucleotide sequence.
Primer Name Use Sequence
Ku70 N-terminal FW
(NdeI)
Ku70 WT-HA pMSCV GGCCTGCATATGAACCTTGAAG
CAAGTGGAGAC
LS Ku HA Rev Ku70 WT-HA pMSCV CCACGAATTCTCAAAGAGCGTA
ATCTGGAACATCGTATGGGTA
CATGTCCTGGAAGT
RV Ku70 Not1 Ku70 pBIG GGGCTGGCGGCCGCTCAGTCCT
GGAAGTGCTTGGT-
GAGGGCTT CC
FW Ku70 BamH1
longer
Ku70 pBIG GGACTAGGATCCATGTCAGGGT
GGGAGTCATATTA-
CAAAAACGA GGGCG
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Appendix B
List of Antibodies
Table B.1: List of antibodies, their relevant dilutions, and source
Antibody Western Blot Dilution IF Dilution Source
HA (H9658) 1:1000 N/A Sigma-Aldrich
Ku86 (C-20) 1:250 N/A Santa Cruz
P-Histone H2A.X (S139)(20E3) N/A 1:1000 Cell Signaling
Ku70 (N3H10) 1:200 1:100 Santa Cruz
Aurora B (ARK-2) (H-75) 1:1000 1:1000 Santa Cruz
T7-tag (D9E1X)(XP) 1:1000 N/A Cell Signaling
P-Histone H3 (S10) 1:1000 N/A Cell Signaling
Vinculin (E1E9V) 1:10000 N/A Cell Signaling
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Appendix C
Ku70 S155D and WT expression
Vinculin
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Figure C.1: Ku70 S155D and WT expression following pMSCV infection. pMSCV S155D
Ku70, WT Ku70, and empty vector constucts were transfected into phoenix cells which were
used to infect Ku70 knockout MEFs. Following puromycin selection of MEFs nuclear extracts
were collected and levels of Ku70 in S155D Ku70, WT Ku70, and empty vector infected cells
were assessed by western blot. Vinculin was analyzed as a loading control.
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Appendix D
Scientific Reports: Publication Rights
Figure D.1: Right to republish data Scientific Reports. As an author of Ku70 Serine 155
mediates Aurora B inhibition and activation of the DNA damage response, I maintain the right
to use the data within my thesis.
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